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ABSTRACT

HORMONE EPIMERS REGULATE ER STRESS AND CORE REGULATORY GENES:
NETWORK ANALYSIS WITH APPLICATIONS TO GLIOMA AND CHRONIC PRESSURE
ULCERS
THOMAS LEE SHAAK, PhD
A Dissertation submitted in partial fulfillment
of the requirements for the degree
Doctor of Philosophy at
Virginia Commonwealth University
Virginia Commonwealth University, 2013
Director: Dr. Robert F. Diegelmann, PhD., Professor of Biochemistry

DHEA has been determined to have medically significant activity and is the parent compound to
the more active metabolites; 17α-AED, 17β-AED and 17β-AET, which exhibit strong biological
activity that has been attributed to androgenic, estrogenic or anti-glucocorticoid activity in vivo
and in vitro. This study compared DHEA, 17α-AED, 17β-AED and 17β-AET for their ability to
activate the human AR, ER and GR receptors and determine the relative androgenicity,
estrogenicity and glucocorticoid activity. The results show that, at the receptor level, these
androstene hormones are weak AR and even weaker ER activators. Direct androstene hormone

activation of the human AR, ERα, and ERβ may not be essential for their biological function.
Similarly, these hormones indirectly activated the human GR receptor; only in the presence of
high dexamethasone concentrations. These results underscore the major difference between
androstene hormone interactions with these nuclear receptors.
17β-AED and 17α-AED, androstene epimers that produce either survival or death, were
utilized to treat T98G Glioblastoma cells. We identified 26 genes oppositely regulated by 17βAED and 17α-AED to directly affect the cellular life or death decision. Network analysis
demonstrated that these 26 genes are essential to regulating three critical Glioblastoma pathways.
This report, for the first time, demonstrates that naturally occurring, chemically identical adrenal
hormones (17β-AED or 17α-AED) direct a cellular life or death decision through contrasting
modulation of identical signaling pathways and core regulators.
Chronic pressure ulcers represent a significant health problem and are characterized by
hypoxia, bacterial infection, repetitive ischemia/reperfusion and altered cellular and systemic
stress responses. Whole genome microarray analysis was utilized in conjunction with IPA®
premiere networking software to analyze chronic wound edge tissue. IPA® network analysis
identified Ubiquitin C (UBC) as the most significant network. Sixteen (16) ubiquitin C
associated genes were identified to be different in the chronic pressure ulcer and normal skin
control. Targeted network analysis associated core regulators to 8 UBC associated genes that are
unique to chronic pressure ulcers. The identification of these genes will allow the establishment
of more effective treatments for Spinal Cord Injury (SCI) patients with chronic pressure ulcers.

CHAPTER 1: Introduction

Historical Perspective: Discovery of the anti-inflammatory effects of corticosteroids
The effects of adrenal insufficiency was first discovered in 1855 by Thomas Addison [1].
In 1939, Butenandt received a Nobel Prize in chemistry for his work on steroid hormones and
steroidogenesis [2]. This work and the work of others at this time period began the study of the
steroid producing endocrine glands. Shortly thereafter, Kendall, Hench and Reichstein were
awarded the Nobel Prize for the discovery of the anti-inflammatory effect of cortisol in
rheumatoid arthritis patients marking the first time an endogenous hormone was discovered with
significant anti-inflammatory effects [3]. This work sparked the clinical use of corticosteroids as
long-term therapeutics for chronic inflammatory diseases. The beneficial effects of
corticosteroids, however, was overshadowed by association with immune suppression and risk of
infection, osteoporosis, thinning of the hair, stria formation, growth inhibition, hematopoietic
abnormalities, psychological changes and delayed wound healing. Glucocorticoids administered
in vivo impair activation of the immune system, increase pathological effects of disease and
increase mortality to viral infections [4]
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Hypothalamus Pituitary Adrenal Axis
It has been know for more than 40 years that an immune response with elevated levels of
circulating cytokines and activated immune cells can stimulate the HPA axis [5]. These
observations were later confirmed in studies utilizing intravenous, intraperitoneal and
intracerebroventricular cytokine studies [6-11]. ACTH stimulation will also increase the serum
levels of adrenal hormones other than cortisol such as dehydroepiandrosterone and
androstenedione [12][13]. These effects can be seen in patients with rheumatoid arthritis or who
are undergoing surgery [14][15]. These reactions may include stimulation of peripheral sensory
nerves [16][15]. Thus, it is not only cortisol but there are other adrenal steroids which are
secreted after a short-term inflammatory stimulus. In this context, it has been demonstrated that
high doses of IL-6 stimulate adrenocortical cells in vitro (92).
Chronic inflammatory diseases, however, are associated with elevated levels of cortisol
and decreased levels of DHEA while, as described above, acute elevations in inflammatory and
immune cytokines increase DHEA and cortisol [17][18]. In long-term inflammatory disease
there is a decreased responsiveness of the HPA axis during extended periods of inflammation
where IL-6 or TNF serum levels are elevated [10]. Cortisol levels act rapidly on hypothalamic
neurons to stop CRH releasing hormone [15]. Ultimately, longer-term elevated proinflammatory
cytokines influence adrenal steroid hormone levels [19][20]. In addition, it was observed that
there exists an age-related increase of serum IL-6 in healthy female and male subjects associating
aging with reduced HPA responsiveness [21].

2

Dehydroepiandrosterone (DHEA)
Dehydroepiandrosterone (DHEA) and its sulfated derivative (DHEA-S) are the most
abundant circulating steroid hormones in humans [22][23]. Despite large amounts of study, the
molecular, cellular, physiological mechanisms of action remain elusive. DHEA is an adrenal
cortical steroid classified as a neurosteroid which is present in high concentrations during
gestation, and age related development [24]. DHEA has been classified as a neurosteroid because
it can be synthesized de novo in the brain [25]. Additionally, astrocytes and neurons will convert
pregnenolone to DHEA in the brain [26].
The levels of DHEA peak during reproductive years and then decline dramatically with
age [27]. DHEA is found to be regulated by the HPA in acute and chronic inflammatory
situations. DHEA, because of its biochemical, physiological, pharmacological, toxicological and
clinical effects sparked intense scientific interest and a multitude of research efforts were
undertaken and are currently ongoing to delineate the beneficial biological effects and action of
DHEA.
DHEA has been intensely studied for its effects in treating cancer [28], viral and bacterial
infection [29][30][350], auto-immune disease [31], arthritis [32], cardiovascular disease [33],
control of body weight [34], stress [30][35], asbestosis [36], neural effects [37], diabetes
(metabolic disease) [38], enzyme regulation [39], anti-oxidant effects [40], protection from
ischemic/reperfusion [41], effects in bone metabolism [42], and an anti-glucocorticoid effect in
promoting immune cell survival and proliferation [43]. DHEA is the parent hormone to its more
active metabolites, however, the multitude and significance of the results obtained from DHEA
are worth noting here for utility and perspective.
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Anticancer effects of DHEA
The effects of anti-carcinogenic effects of DHEA have been well studied. DHEA was
shown to produce a decline in tumor burden in castrated mice with human prostate tumors that
were propagated in nude mice [28]. Subsequently, fluorinated DHEA was studied because did
not convert into estrogen and testosterone [44]. It was shown that 16 alpha-fluoro-5-androsten17-one, a non-androgenic DHEA analogue, significantly decreased the incidence of small
intestinal tumors however, an increased dose was not as effective [45]. DHEA and 16 alphafluoro-5-androsten-17-one reduced tumor initiation, tumor promoter-induced epidermal
hyperplasia and promotion of papillomas in the two stage skin tumorigenesis model [46].
Together these observations suggested that DHEA alone has some anticancer effects although
some activity may be attributed to its metabolites.
DHEA was found to reduce the incidence and multiplicity during both phases of
mammary cancer and incidence was most affected by DHEA together with 4-HPR(n-(4hydroxyphenyl) retinamide) [47]. DHEA also delayed tumor development in p53 knockout mice
[48]. DHEA also was associated with increased bone density and lowered serum triglyceride
levels in rats with DMBA-induced mammary cancer [49]. Many more studies have associated
DHEA with anti-cancer effects [50-53] to name a few. It must be noted that Hamilton et al.
paradoxically found that DHEA actually increased colon tumor incidence when male F344 mice
were fed 0.5% DHEA for 7 weeks beginning one day after the administration of azoxymethane
[54].
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Immune effects and DHEA
Multiple reports of the anti-viral effects of DHEA were reported in the 1990's. It was
reported that DHEA administration to C57BL/6 mice infected with Murine retrovirus opposed
retrovirus induced oxidative damage and loss of immune cytokines (IL-2, IFNγ) [55]. In these
studies, DHEA opposed IL-6 and TNFα production by T helper 2 cells (TH2) and DHEA-S was
found to oppose retrovirus induced T cell reduction in old mice. Subsequently, the effects of
DHEA administration on lethal viral infections was studied and it was found that a single
subcutaneous dose of DHEA was able to upregulate the immune response and provide protection
against of lethal infective titers of Herpes virus type 2 encephalitis or systemic Coxsackievirus
B4 infection [56][350]. Subsequent studies demonstrated that DHEA/DHEA-S could provide
significant benefits against immunodeficiency viruses by decreasing virus replication in vitro and
provided protection against retrovirus-induced lipid peroxidation in the heart in vivo [57-59].
The ability of DHEA to influence lipopolysaccharide (LPS)-induced TNFα and
endotoxic shock was studied and the results demonstrated that DHEA significantly reduced the
levels of LPS-induced TNFα and serum corticosterone levels which shows that DHEA is also
influencing the stress response. The ability of DHEA to influence resuscitative trauma and the
post-traumatic effect of LPS on the systemic inflammatory response was examined [60]. The
results demonstrated that DHEA was insufficient in a pig model to protect against progressive
shock and pulmonary failure at 4, 10 and 20 mg/kg doses administered at 1, 24, 48 and 72 hours
after trauma.
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Anti-autoimmune effects and DHEA
It was discovered that 200mg/day of DHEA decreased systemic lupus erythematosus
(SLE) activity [61]. Later clinical studies by this same group demonstrated that DHEA treatment
alleviated SLE symptoms and systemic manifestations [31]. Subsequently, cytokine studies
demonstrated that DHEA levels were found to be low in SLE patients and that DHEA
upregulated IL-2 production of normal T cells and reversed the effects of SLE in these patients
[62][63]. These results prompted suggestions that low levels of DHEA may be responsible for
defects in IL-2 synthesis [62]. Additionally, it was reported that DHEA also reduced the
incidence and severity of collagen-induced arthritis [32]. DHEA-S was subsequently shown to be
increased after TNFα inhibition in rheumatoid arthritis patients [64]. Together, these results
strongly suggest that low DHEA in conjuction with TNFα levels underlie these diseases.

Neural effects and DHEA
It was discovered that DHEA (500mg) given orally to normal subjects induced significant
increases in rapid eye movement (REM) sleep during the first 2 hour sleep period [65]. These
studies demonstrated that DHEA had different effects at different stages of sleep suggesting that
DHEA had a mixed GABA-A agonist/antagonist response [65]. DHEA, administered
intracerebroventricularly, was found to improve memory and it was postulated that DHEA
converged as a transcription facilitator for immediate -memory functional genes[66]. Another
group discovered that DHEA administration over 18 months resulted in counteracting the ageinduced suppression of CRH mRNA levels in the hypothalamic periventricular nucleus of both
sexes [67]. Additionally, it was found that the decline in DHEA levels in aged people may be
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related to pathological amyloid precursor protein metabolism[68]. These results strongly
demonstrate a link between the HPA axis, low DHEA and age-related dementia.

DHEA, stress and the anti-glucocorticoid Response
In an elegant experiment, it was shown that mice inoculated with West Nile Virus and
subjected to cold stress followed by serial injection with DHEA(10-20 mg/kg) were protected
from viral infection in the blood, brain and lymphoid organs [30] providing additional support
that DHEA is an anti-stress agent. DHEA was also utilized to treat high and low anxiety in rats
and it was reported that DHEA significantly decreased behavioral despair associated with high
anxiety while there was no significant effects noted in rats with low anxiety [35]. DHEA was
also administered to sound stressed male Sprague-Dawley rats and it was noted that DHEA
blocked the stress induced tryptophan hydroxylase activity in the mid-brain and cortex regions of
the brain [69]. In these experiments DHEA was administered in conjunction with estrogen,
progesterone, testosterone and a glucocorticoid agonist and found that estrogen, testosterone and
progesterone had no effect in blocking sound stress induced tryptophan hydroxylase activity
while DHEA alone or in combination with the glucocorticoid inhibitor blocked sound stress.
Tryptophan hydroxylase is an enzyme that is increased by glucocorticoids and limits the
production of 5-hydroxytryptamine the ligand of the serotonin receptors [70]. Furthermore these
receptors are responsible for modulating and releasing multiple neurotransmitters including
GABA [71]. Glucocorticoid activity (RU 28362) did not increase the sound stress-induced
production of tryptophan hydroxylase in the presence of DHEA and it was suggested that DHEA
achieved this activity through antiglucocorticoid action [69]. It was discovered that high dose
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DHEA pretreatment antagonized dexamethasone-induced thymic and splenic atrophy at 60
mg/kg while low doses (10-7 to 10-8 M) did not provide protection [43].
In addition, it was reported that DHEA alone would not block tyrosine aminotransferase
(a glucocorticoid induced enzyme), however DHEA in the presence of dexamethasone blocked
dexamethasone induced suppression of tyrosine aminotransferase and ornithine decarboxylase in
a time and dose dependent fashion demonstrating the DHEA association with glucocorticoid
transcribed genes [72][73]. Studies on the effects of DHEA on levels of the glucocorticoid
receptor demonstrated that levels of the glucocorticoid receptor were significantly reduced by
DHEA [74]. Together, these observations demonstrate that complex interactions are occurring
that involve DHEA, the glucocorticoid receptor and influence the transcriptional responses
affecting immune responses, cancer and stress.

DHEA as a precursor to androstene hormones
The effects of DHEA have commonly been performed in animal models. DHEA
administered as a food admixture resulted in female rats obtaining plasma levels of DHEA that
were an order higher than that of the male rats [75][76]. Tissue distribution of DHEA was
subsequently studied in male and female Sprague-Dawley rats following oral administration and
it was observed that there were no main sex differences between male and female rats[74].
DHEA levels rapidly decreased within 24 hours and was found to be primarily retained mainly in
the liver, kidney, pituitary and bone marrow [74]. The presence of radioactive DHEA was
observed in the pituitary and bone marrow even when levels of radioactivity were significantly
decreased [74].
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A significant difference in DHEA excretion was found to exist between males and
females. Male rats excrete DHEA in the faeces while female rats excrete DHEA metabolites in
the urine [74]. Both sexes excrete the DHEA metabolites in the first 24 hours after ingestion
[74]. While sex differences in excretion exist between serum, urine, bile, liver and faeces, the
metabolite that was found to be present in the greatest concentration was Δ5-androstene-3β, 17βdiol (17β-AED) in female rats and more polar DHEA metabolites including Δ5-androstene-3β,
17β-diol (17β-AED) in males [74]. The presence of polar metabolites to dominate demonstrated
that these metabolites may have significance. It was observed that DHEA is only found in trace
amounts after administration and excreted polar metabolites with a hydroxyl group in the 7
position were present. Importantly, 7-hydoxylated steroids had been observed to have an
important role in the immune stimulation of mice [77][78]. Thus, in addition to DHEA,
considerable attention has been given to the study of 17β-AED, and Δ5-androstene-3β, 17β-triol
(17β-AET).

Δ5-androstene-3β, 17β-diol (17β-AED) and Δ5- androstene 3β, 17β-diol (17β-AET) Metabolism
Δ5-androstene-3β, 17β-diol (17β-AED) is one of the primary metabolites derived from
DHEA. 17β-AED is a derivative of DHEA which results from conversion of the keto group to
a hydroxyl group at the 17 position [74]. 17β-AED is hydroxylated at the 7 position before Δ5androstene-3β, 17β-triol (17β-AET) can be formed [79]. The biological activity of DHEA, 17βAED, 17β-AET has been demonstrated to occur through the subcutaneous route [80][81]. The
skin, in turn, has been shown to contain all the necessary enzymes to convert DHEA to 17β-AED
and 17β-AET [82-85]. 17β-AED metabolism has been evaluated in men and women and it has
been found circulating in the serum [86][87]. Metabolism of Δ5-androstene-3β, 17β-diol (17β-
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AED) was evaluated and found to be comparable in men and women and was converted into
DHEA, 17β-AED sulfate and DHEA-S [87]. An important observation is that DHEA can be
transformed into 17β-AED and conversely, 17β-AED can be transformed back to DHEA
[74][87]. This indicates that some interconversion can occur which may be related to DHEA or
17β-AED functionality where this interconversion occurs.

DHEA, Δ5- androstene-3β, 17β-diol (17β-AED), Δ5- androstene-3β, 7β, 17β-triol (17β-AET),
immunity and antiglucocorticoid activity
Δ5-androstene-3β, 17β-diol (17β-AED) is a DHEA metabolite that possesses
considerable ability to upregulate immunity in a generalized and non-specific fashion [88]. It was
determined that DHEA was not the active agent that induced the host immune response [80].
Consequently, it was shown that 17β-AED, at 1/3 the dose of DHEA, is at least 100 times more
effective than DHEA at increasing host immunity needed to protect against many different types
of infection including viral, bacterial, parasitic and non-infectious agents [90]. 17β-AET
possesses 10,000 times the efficacy of inducing the host immune response than is DHEA [89].
17β-AED was tested in vivo to determine the most effective route of administration and
effective dosage [91]. It was shown that 17β-AED, by the cutaneous route, would protect against
lethal infection at 20, 80 or 160 mg/kg doses, however, it was determined that only 320 mg/kg
17β-AED only in the presence of an antigen would induce spleen and thymus proliferation [91].
This is in contrast to DHEA which did not induce spleen or thymus proliferation [91]. In these
studies, heart destruction by coxsackie virus-induced cytotoxic lymphocytic activity was noted to
be absent when 17β-AED was present thus demonstrating that host cytotoxic lymphocyte
activity was inhibited even in the presence of the infecting virus indicating that a non-
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glucocorticoid, anti-inflammatory action could be achieved through host immune modulation
[91].
DHEA and 17β-AED were studied for their ability to protect mice against lethal bacterial
infection and LPS toxicity [88]. 17β-AED was shown to have no effect on TNFα levels that was
induced to an in vivo LPS challenge in mice [88]. In opposition and similarly to glucocorticoids ,
DHEA inhibited TNFα concentration in these studies [29][88]. Furthermore, in vitro experiments
with RAW 264.7 macrophages demonstrated the same effects that were seen in vivo[88].
In addition to DHEA and 17β-AED, Δ5-androstene-3β, 7β, 17β-triol (17β-AET ) was
synthesized and found to be even more potent than 17β-AED in upregulating the immune
response in vivo [81]. 17β-AET was also found to possess anti-glucocorticoid activity [92].
Mitogen treated spleen cells were exposed to 17β-AET, 17β-AED and DHEA and it was
reported that 17β-AET increased IL-2 and IL-3 while 17β-AED had no effect and DHEA
decreased the levels of these two cytokines that are suppressed by glucocorticoids [92]. Because
17β-AED and 17β-AET were effective in upregulating host immunity in vivo and displayed antiglucocorticoid activity that was different from DHEA and each other, further studies were
pursued to further examine the anti-glucocorticoid effects on immune mediating macrophages
and lymphocytes.
Studies were performed with DHEA and 17β-AED on the ability of these androstene
hormones to counteract the action of glucocorticoids on macrophages and lymphocytes in vitro
[93][78]. Glucocorticoids have been reported to downregulate TNFα, IL-1, and IL-6 [94-96]. In
LPS stimulated RAW264.7 macrophages, 17β-AET increased IL-1 and TNFα, 17β-AED did not
affect IL-1 or TNFα, while DHEA decreased both IL-1 and TNFα [97]. Strikingly, all three
androstene hormones decreased IL-6 to the same level as hydrocortisone in these cells [93]. In
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mitogen stimulated lymphocytes a similar pattern was noted for IL-2 and IL-3 suppression by
hydrocortisone where 17β-AET in the presence of hydrocortisone significantly increased IL-2
and IL-3, 17β-AED increased IL-2 and IL-3 at high concentrations to levels lower than 17βAET, while DHEA maintained levels of IL-2 and IL-3 at the same level as the hydrocortisone
control [78]. Together, these results demonstrate that immune mediating macrophages and
lymphocytes respond differentially to DHEA, 17β-AED and 17β-AET and display an increasing
anti-glucocorticoid and immune functionality from DHEA to 17β-AED to 17β-AET.
Together, these results demonstrate that DHEA, 17β-AED and 17β-AET differentially
regulate immune responses in vivo and in vitro and also possess differential activity with
glucocorticoids. Because DHEA, 17β-AED and 17β-AET possess different anti-glucocorticoid
activity in vivo and in vitro then open questions are 1) Do they each interact with the
glucocorticoid receptor differently at the level of the glucocorticoid receptor? and 2) Do they
each interact with the glucocorticoid receptor at all?

Transcriptional Effects of 17β-AED and 17β-AET
DHEA, 17β-AED and 17β-AET possess different anti-glucocorticoid activity in vivo and
in vitro. Glucocorticoids and gamma irradiation both induce immune injury. Glucocorticoids
cause destruction of lymphoid cells and alters RNA synthesis [4]. Gamma irradiation damages
genetic material in all blood components and mediates destruction of lymphocytes[98]. Thus,
and 17β-AET were evaluated on their ability to counteract the damaging effects of whole body
ionizing radiation [99-101]. It was discovered that not only did 17β-AED and 17β-AET protect
against a lethal radiation dose of 8Gy(800 rad) at subcutaneously administered concentrations of
320 mg/kg for 17β-AED and 30 mg/kg for 17β-AET but also increased immune protection
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against Coxsackie B4 virus as they did with unirradiated animals [81]. Together, these results
demonstrate that both 17β-AED and 17β-AET produce survival against the damaging and
destructive effects of lethal irradiation and at the same time restore the immune effects.
Ultimately, it was discovered that 17β-AED stimulated protection and accelerated multilineage blood cell recovery and elevated bone marrow (BM) cellularity [101]. Spleen colonyforming unit assays showed that combined treatment with 5-AED plus thrombopoietin resulted
in a 3 to 4 fold increase as opposed to 5-AED and TPO alone [101]. In opposition to
thrombopoietin, 17β-AED demonstrated protection and survival of bone marrow progenitors
[100] [101]. These studies identified transcription factors and cytokines present in the response
to irradiation 17β-AED was associated with elevation of GM-CSF, IL-2, IL-3, IL-6 and IL-10 in
the spleen before irradiation and GM-CSF, IL-2 in bone marrow. Post-irradiation G-CSF, GMCSF, Interferon gamma, thrombopoietin, IL-2, IL-3, IL-6, IL-10 and IL-12 were all elevated in
spleen and GM-CSF, interferon gamma, thrombopoietin, IL-3 and IL-10 in bone marrow [102]
Expression of G-CSF was associated with the master transcriptional regulator: NFkB1 in
response to irradiation [100][103]. Because increased levels of CDKN1A, BCL2, BAX and
DDB1 were observed, 17β-AED was associated with cellular programs of DNA damage
prevention, cell cycle progression and apoptosis. These results demonstrate that 17β-AED,
through a program distinct from thrombopoietin, will direct the expression of cytokines in
response to irradiation and suggest that these cytokines are the result of a transcriptional program
inclusive of NFkB1.
17β-AED and 17β-AET possess different anti-glucocorticoid activity in vivo and in vitro
and demonstrated ability to direct transcriptional programs that result in survival in response to
stress. 17β-AED and 17β-AET were subsequently tested for their ability to improve otherwise
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depressed cardiac function and cytokines after trauma hemorrhage [104]. It was observed that
17β-AED significantly improved blood flow in the liver, brain, kidney, pancreas, spleen and
adrenal glands, significantly reduced IL-6, and raised nitrates/nitrites [104]. It was also reported
that 17β-AED improved hepatic portal function through decreasing endothelin-1 and increasing
eNOS [105].
Subsequently, it was reported that peroxisome proliferator activated-receptor gamma
(PPARγ) was at least, in part, responsible for the beneficial decrease in IL-6 and iNOS [106].
17β-AET also was found to provide protection against trauma hemorrhage and it was reported
that 17β-AET decreased IL-6 while increasing IL-2 and IFNγ in the spleen [107][108]. Together
these observations demonstrate that 17β-AED and 17β-AET induction of transcriptional
programs resulting in survival that are at least, in part, mediated by transcriptional master
regulators (PPARγ).
17β-AED possesses anti-glucocorticoid activity in vivo and in vitro. Stress and the
glucocorticoid receptor (GCR) are known to delay wound healing [109-112]. Blockade of the
GCR increased IL-1β and keratinocyte growth factor 1 KGF-1 levels in these studies and
increased wound cellularity and returned wound healing to normal [109]. Similarly, 17β-AED
reversed glucocorticoid suppression of IL-1β and PDGF [112]. 17β-AED thus appears to also
affect gene expression patterns in cutaneous wounds through the GCR transcriptional regulator.

DHEA, 17β-AED, 17β-AET and the estrogen/androgen receptors
Estrogen and Androgen are master transcription regulators that are members of the
nuclear receptor superfamily [113]. Cutaneous wound healing and neuroprotective activity has
generally been attributed to estrogen derived from DHEA [26][114-116]. Subsequently, it has
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been demonstrated that cutaneous wound healing is associated with the action of the estrogen
receptor beta (ERβ) and that androgen opposed the action of ERβ [117]. 17β-AED has inherent
androgenic and estrogenic properties [118-120]. Furthermore, studies of trauma-hemorrhage
have associated increased NFkB and activator protein-1 (AP-1) with increased IL-6 and TNFα
[121]. Normalization of all these proteins was obtained by 17β-estradiol and was associated with
PPARγ [121]. These observations have led some to hypothesize that androstene hormones may
function similarly to estrogen [122].
It has been known for some time that 17β-AED possesses both androgenic and estrogenic
activity [123]. Several studies demonstrate the activation of the estrogen and androgen receptor
by C19 steroids with resultant "estrogenic effects" (i.e. gain in uterine weight) "androgenic
effects" (i.e. hirsutism), or proliferation of human mammary cancer cells [124-130]. A "google
scholar" search of "estrogen and proliferation" returned 685,000 results while the same search
with androgen yielded 163,000 results. Clearly, androgen and estrogen are associated with
proliferation. It was noted that 17β-AED was present in high concentrations in some
proliferative diseases, mainly breast cancer [131] and prostate cancer [132]. Some studies
reported that androgenic metabolites may compete with 17β-estradiol and translocated the
estrogen receptor in the uterus and mammary tumors [133-137]. Thus, it was thought that 17βAED, either itself or as a metabolite, was responsible for cellular proliferation through an
interaction with either the androgen or estrogen receptor.
It was found that in mammary cancer, estrogen stimulated MCF-1, ZR-75, T47-D and
EFM-19 cells [138-141]. It was reported that high concentrations of androgen enhanced growth
of EFM-19 and MCF-7 [141][142] cells while physiological concentrations of androgen were
inhibitory in ZR-75-1 and MFM-223 cells[143][144]. Estrogen and androgen receptors were
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present and found in different concentrations in all of these cell lines [144]. Subsequently, 17βAED was tested on MFM-223 (high androgen receptors and low estrogen receptors) and MCF-7
(low androgen receptors and high estrogen receptors) breast cancer cells [145]. 17β-AED was
found to be inhibitory in the MFM-223 cells and growth promoting in MCF-7 cells [145]. These
studies demonstrated that it took 3 orders of magnitude greater concentration of 17β-AED to
cause the proliferative effect in conjunction with the estrogen receptor while the inhibitory effect
of 17β-AED on MFM-223 cells was only partially reversed through cyproterone acetate [145].
It has been shown through structural modeling of the estrogen receptor alpha binding
pocket that this receptor can accommodate many molecules including 17β-AED [146].
Additionally, it is mentioned that Δ5-steroids, including 17β-AED, may be ancestral ligands of
the estrogen receptor [146]. Interestingly, because the estrogen receptor is believed to have
undergone convergent evolution this may imply a different functionality for 17β-AED [147].
These results demonstrate that indeed 17β-AED may compete with 17β-estradiol and affect its
structure and function.
These results demonstrate that 17β-AED interacts differently than either estrogen or
testosterone and that the biological effects are dictated by the composition of the cells. Since,
there can be opposing effects within the same cell type; it is unclear the effects of DHEA are due
strictly to the estrogen and androgen receptors. Recently, it was shown that 17β-AED is antiinflammatory in a model of experimental autoimmune encephalitis [148]. It was shown that 17βAED and not 17β-estradiol inhibited lipopolysaccharide induced IL-6 through a mechanism that
involved 17β-AED binding the estrogen receptor beta along with the recruitment of CtBP to
tether and suppress the activity of cFos [148] . This suppressive action of 17β-AED is clearly
different than the actions of 17β-estradiol on the estrogen receptor.
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17β-AED was shown to mechanistically interact with cFos and influence IL-6 differently
than 17β-estradiol [148]. These observations further implicate the 17β-AED influence of gene
expression in the presence of inflammatory stimuli through another master transcriptional
regulator (cFos), in addition to those already discussed (NFkB and PPAR). Thus, the
transcription factors that have been studied and reported for DHEA and 17β-AED so far
resemble the same transcription factors reported for 17β-estradiol. The biological actions and
mechanistic effects, however, are clearly different. Together, the differences in the immune
regulation and in anti-glucocorticoid activity attributed to DHEA, 17β-AED and 17β-AET
indicate that these receptors may have different interactions at the level of the ER and AR
receptors.

Δ5-androstene-3β, 17α-diol (17α-AED)
17β-AED and 17α-AED are chemically identical and the only difference is the position of
the hydroxyl group at the 17-position [149]. 17β-AED is derived from DHEA. 17α-AED is
another C19 Δ5-steroid that, like 17β-AED is produced in the testes[150][151]. 17α-AED is
found in the amniotic fluid and fetal-placental circulation during pregnancy with the ratio of 17αAED to 17β-AED of 9:1 in favor of 17α-AED. In adulthood the ratio is 2:1 in favor of 17β-AED
[150][151]. 17α-AED and 17β-AED have been associated with epitestosterone production in the
human testes [152]. Additionally, while it has not been confirmed, 17β-AED and epitestosterone
have been shown to be formed in the human ovarian follicular fluid [153]. Low levels of 17αAED have been associated with toxemia, diabetes and placental insufficiency [152].
17α-AED was originally tested for biological activity on myeloid oncogenic cell lines
[154]. It was reported that 17α-AED had an anti-proliferative effect on murine macrophage 264.7
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macrophages, murine p388D1 lymphoid neoplasm cells, human promyelocytic leukemia (HL60) cells demonstrating an anti-proliferative effect across three different types of myeloid cell
types [154]. Additionally, 17α-AED at 50 nM was shown to produce irreversible apoptosis
shown by electron microscopy in 2 (HL-60 and Raw 364.7) of the 3 cell lines while 17β-AED,
the epimer of 17α-AED, at the same concentration did not produce cell death.
HL-60 cells were treated with either 17β-AED or 17α-AED and it was discovered that
17β-AED at all concentrations promoted incorporation of [3H] thymidine and thus demonstrated
DNA synthesis as opposed to 17α-AED which at concentrations at or above 12.5 nM didn't
promote [3H] thymidine uptake [154]. The [3H] thymidine uptake test was also performed for
Raw 264.7 cells and it was demonstrated that [3H] thymidine uptake was inhibited at 17α-AED
concentrations at or above 50 nM and, in this cell line, 17β-AED produced a decrease in the [3H]
thymidine uptake at levels at or above 500 nM [154]. In the p388D1 lymphoid cells, 17α-AED
produced a significant reduction in [3H] thymidine uptake and produced an anti-proliferative
effect at concentrations at or above 12.25 nM while 17β-AED did not decrease DNA synthesis at
any concentration [154]. Together, these results show that DNA synthesis correlated with an
anti-proliferative effect for 17α-AED and a proliferative effect for 17β-AED in these myeloid
cells lines.
Because anti-proliferative effects were demonstrated by 17α-AED on the myeloid cell
lines this epimer of 17β-AED was tested for anti-proliferative ability in the ZR75-1 (estrogen
positive) and MDA-MB231 (estrogen negative) human mammary cancer cell lines [155].
Because the chemically identical epimer, 17β-AED, is produced in primary breast tumors [156]
and 17β-AED is known to possess an ability to interact with the estrogen and androgen receptors
[119], these tests were performed in the ZR75-1 and MDA-MB231 cell lines.
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The results demonstrated that similar to myeloid cells, 17α-AED inhibited proliferation
of ZR75-1 and MDA-MB231 cells between the concentration of 12.5 to 50 nM [155]. These
studies were repeated with flutamide blocked androgen receptors and no change was noted in the
anti-proliferative ability of 17α-AED on both cell lines [155]. 17α-AED was tested
simultaneously with 17β-estradiol on the ZR75-1 cells and an enhanced anti-proliferative effect
was noted [155]. 17β-AED and 17α-AED were tested simultaneously on ZR75-1 cells and a
profound decrease in proliferation was noted [155].
It was shown in separate experiments with the estrogen inhibitor, tamoxifen and the
androgen inhibitor flutamide that 17β-AED appeared to have anti-proliferative effects on MCF-7
cells(androgen and estrogen receptor positive) through the androgen receptor and proliferative
effects through the estrogen receptor. Together, these studies associate 17β-AED with estrogen
and androgen activity, which was shown to be dependent on the receptor content and "growth
properties" of the cells [119] and that 17α-AED will oppose these activities independent of the
androgen and estrogen receptors.
17α-AED produced anti-proliferative effects in different cell lines. DHEA, 17β-AED,
17β-AET and 17α-AED are derived from neural tissue. With 17α-AED producing antiproliferative, and in most cases cell death, these hormones were tested for cytotoxic ability on
T98G Glioblastoma and U937 Lymphoma cells [157]. 17α-AED produced irreversible cell death
by autophagy at doses above 15uM (90% inhibition at 25uM) in T98G cells and apoptosis in
U937 Lymphoma cells. In contrast, DHEA, 17β-AED and 17β-AET did not produce cell death.
17α-AED was then tested on GBM6, T98G, U87MG, LN-18, LM-Z308 Glioblastoma cells[158].
All cell lines could be induced to enter irreversible cell death by autophagy and at IC 50
concentrations between 8 and 25uM [158]. Additionally, it was discovered that 17α-AED

19

reduced AKT/mTOR signaling and induced autophagy through the induction of ATG5 and
beclin-1 in these cell lines. Together, these observations suggested a mechanism that could
induce different irreversible programmed death pathways in different cell types.
A hallmark of steroid hormones is that slight changes in hormone structure can lead to
significant differences in biological functionality [159]. Due to this characteristic of steroid
hormones, 6 androstene hormones with the hydroxyl groups at different positions were
synthesized and tested to determine cytoxic effects on T98G Glioblastoma and U937 Lymphoma
cells[160]. It was discovered that the position and orientation of the hydroxyl group at the 17
position in relation to the cycloperhydrophenanthrene steroid ring and not the hydroxyl located at
the 3 position was responsible for either autophagy or the apoptotic effect on Glioblastoma and
Lymphoma cells respectively [160]. These observations suggest that the hydroxyl at the 17
position impart 17α-AED with the ability to direct different programmed cell death pathways in
different cell types and that these effects are through estrogen/androgen independent means.
Because 17α-AED and 17β-AED, other than the orientation of the hydroxyl group at the 17
position, are chemically identical, it is possible that 17α-AED could fit in the estrogen and
androgen ligand binding pocket. Despite the anti-proliferative activity, it is currently unknown
whether 17α-AED interacts with the androgen and estrogen receptors.
Pursuant to these observations, the mechanism of action of 17α-AED was investigated
[161]. LN-18, LN-229, U87MG, LN-Z308, U251MG Glioblastoma cells were treated with 17αAED and members of the unfolded protein response were investigated since prior results
implicated ATG5 and beclin-1 suggesting that a class III PI3K/p150 lipase signaling complex
was involved [161]. Experiments were performed utilizing these multiple cell lines and T98G
Glioblastoma cells transfected with either a double negative mutant PERK or an empty vector
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control [159]. The results demonstrated that 17α-AED activated the double stranded RNAactivated protein kinase (PKR)-like endoplasmic reticulum kinase (PERK) and not interferoninducible double stranded RNA dependent activator kinase (PKR), the eukaryotic translation
initiation factor 2 alpha kinase 4 (GCN2) or the eukaryotic translation initiation factor 2-alpha
kinase 1 (HRI) [161]. It was then further shown that phosphorylation of eLF2α occurred
downstream of PERK activation which is consistent with translation attenuation [161].
Additionally, it was shown that the X-box binding protein 1 (XBP-1) was not cleaved while
CCAAT/enhancer binding protein homologous protein (CHOP), glucose regulated protein of 78
kDa (GP78) were elevated which further suggest a specific mechanism of action [161]. Together,
these observations demonstrate that 17α-AED possesses mechanisms of action that are
independent of estrogen and androgen receptors.
The unfolded protein response (UPR) typically involve the three endoplasmic reticulum
transmembrane receptors: activating transcription factor 6 (ATF6), inositol requiring kinase
(IRE1) and double stranded RNA-activated protein kinase (PKR)-like endoplasmic reticulum
kinase (PERK) [162]. The UPR performs three functions; adaptation, alarm, and apoptosis [162].
Adaptation is associated with a translational block and expression of chaperones to aid in
refolding [162]. If this is unsuccessful then the alarm phase is initiated which is associated
initiation of signal transduction events that lead to removal of the translational block,
downregulation of survival proteins (B-cell CLL/lymphoma 2 (BCL2)) and after the alarm phase
ER stress can activate programmed cell death [162].
While the activation of PERK by 17α-AED could be associated with a UPR, there are a
few observations that are different from an ER unfolded protein response. First, the UPR is
associated with IRE1 and ATF6 activation [162]. There was no activation of XBP-1 or activation
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of either the IRE1 or ATF6 by 17α-AED [161]. The translational block was not released during
autophagy induced in the Glioblastoma cells by the 17α-AED thus the translational block
accompanied the induction of autophagy. Last, there was an expression of Grp78 which is
consistent with the adaptation stage of the UPR. These results are consistent with a direct
activation of PERK along with a sustained translational block leading to irreversible
programmed cell death. The upregulation of CHOP and the signal transduction modulation
implied by AKT/mTOR [158] suggests that there are specific transcriptional events that are
associated with the activation of PERK by 17α-AED, however, further knowledge of these
events are currently unknown.

Overview
The observations presented in this brief introduction of DHEA, 17β-AED, 17β-AET and 17αAED were intended to demonstrate the observations central to the idea that the androstene
hormones exhibit a specific biological functionality that is dependent on their structure and
conformation. The androstene hormones have been associated with the medically critical, cellspecific responses of repair and survival or death. The wide range of beneficial effects
demonstrated by the androstene hormones are associated with receptors and cytokines that are
transcriptionally regulated by master transcription regulators that include NFkB, cFOS) and
members of the nuclear receptor superfamily (AR, ERα, ERβ, GR).
This dissertation was based on three hypotheses. In Chapter 1, the operating hypothesis
is: Androstene Hormones, based on their putative ability to interact with the androgen and
estrogen receptors and yet promote differential anti-glucocorticoid activity, will demonstrate
differential activation of the human ERα, ERβ, AR and GR, at the level of the receptor and will
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demonstrate decreased androgenicity or estrogenicity compared to 17β-estradiol and
testosterone. In Chapter 2, because 17α-AED but not 17β-AED induces irreversible autophagy in
Glioblastoma cells and that induction is associated with the chemical structure and conformation
(specifically the hydroxyl group at the 17 position) of 17β-AED and 17α-AED then the operating
hypothesis is: 17β-AED and 17α-AED will be associated with unique transcriptional regulation
in Glioblastoma cells. Finally, in chapter 3, because 17β-AED regulates host resistance through
skin associated immunity and possesses the ability to regulate transcription we tested the
hypothesis that transcriptional regulators modulated by 17β-AED would influence genes which
are significantly active in the pressure ulcer wound edges in comparison to the normal skin.
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CHAPTER 2: Structural Stereochemistry of Androstene Hormones Determines Interactions with
Human Androgen, Estrogen, and Glucocorticoid Receptors
Introduction
DHEA, an androstene hormone, has been shown to possess a wide range of beneficial
biological effects mainly attributed to immune system modulation [163]. DHEA, is metabolized
into more active metabolites i.e., 17β-AED, 17β-AET as well as testosterone and estradiol
[163][164]. 17β-AED and 17β-AET have been reported to prevent the morbidity and mortality of
otherwise lethal infections [89][165] potentiate lymphocyte activation and counteract the
immune suppressive action of hydrocortisone [166][167] thus leading to beneficial effects in
diverse human diseases including resistance to infection, neuroprotection, wound healing,
diabetes, hepatic injury, cardiovascular disease and cancer [168-170].
17α-AED mediates autophagy of glial and breast cancers and apoptosis of myeloid tumor
cells [154][160][171]. 17β-AED and 17α-AED naturally exist in epimeric forms based on
whether the hydroxyl group is above (β) or below (α) the Δ5 cycloperhydrophenanthrene ring.
Addition of a hydroxyl group at the C7 position to 17β-AED results in the formation of Δ5androstene-3β, 7β, 17β-triol (17β-AET). The biological activities of 17α-AED, 17β-AED and
17β-AET have exhibited a structure-activity relationship that depends on the orientation and
location of the hydroxyl groups [172]. Androstene hormones (AH) have been shown to
promulgate their biological effects in many different animal models including mice, rats,
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monkeys and some specific human tissues. Reports have associated the mechanism of action of
androstene hormone metabolites with androgen, estrogen and glucocorticoid receptor activity
[112][118][145]. Adrenal hormones have been shown to activate both androgen and estrogen
constructs. In this regard, it has been documented that 17β-AED can activate the AR receptor in
prostate tissue in the presence of commonly used anti-androgens [173]. Inhibitors of both the
androgen receptor and the estrogen receptors demonstrated that AR and ERβ receptors combine
to affect gene transcription [174] Additionally, 17β-AED was recently shown to be a part of an
anti-inflammatory mechanism that utilizes the ERβ [148]. 17β-AED and 17β-AET have been
documented in vitro and in vivo to oppose the action of hydrocortisone indicating that there may
be crosstalk with the GR receptor [78][91][92].
DHEA has been shown to possess weak androgenicity and estrogenicity [175]. Because 17αAED, 17β-AED and 17β-AET are more potent metabolites of DHEA that exhibit strong
biological activity that could be attributed to androgenic, estrogenic or anti-glucocorticoid
activity in vivo and in vitro it was advantageous to identify whether or not this is directly
mediated by the human ER, AR and GR receptors at the cellular level. Additionally,
androstenediol has been modeled as a chemical with a 3β-hydroxy and a saturated A ring which
can act as an estrogen [176]. Consequently, we compared DHEA, 17α-AED, 17β-AED and 17βAET in the Indigo Biosciences nuclear receptor assay system for their ability to activate the
human AR, ER and GR receptors and determine the relative androgenicity and estrogenicity of
these androstene hormone derivatives.
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Methods
Nuclear Receptor Transactivation Assays
Nuclear receptor transactivation assays were obtained from Indigo Biosciences(State
College, PA, USA) and were utilized to assess activation of human AR, ERβ and ERα. receptors.
Briefly, stocks of the compounds tested were prepared and diluted in medium provided by the
manufacturer. Cell medium was tested for hormone activity by mass spectrometry. Frozen
reporter cells provided in the assay kit were thawed and compound dilutions were added
immediately. Cells were incubated for 24 hours and the activation response was measured on a
luminometer (Perkin-Elmer, MA,,USA). The cells consisted of non-human mammalian cells
engineered by Indigo Biosciences to provide constitutive high-level expression of full length,
unmodified human androgen Receptor (NR3C4), human estrogen receptor 1 (NR3A1), human
estrogen receptor 2 (NR3A2) and of full length, human glucocorticoid Receptor (NR3C1).
The non-human mammalian reporter cells included a luciferase reporter gene functionally
linked to a human nuclear receptor-responsive promoter. The cells are engineered so that only
interactions with the human receptor will induce luciferase expression in the treated reporter
cells to quantitate nuclear receptor activation. Positive control ligand performance was measured
by the manufacturer and provided in the technical manuals thus allowing accurate comparison
for assay performance. Additionally the control ligands of the receptors (testosterone, 17βestradiol, dexamethasone) were tested on the same test plates (n=3 to allow statistical analysis)
with the androstene hormones and controls.
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Preparation of Stock Hormone Solutions
Stock solutions of 17β-AED, 17α-AED, Testosterone (Sigma-Aldrich, St. Louis, MO, USA)
were prepared by dissolving the compounds into 100% ethanol to a final 50 mM stock solution
concentration; 17β-AET was also a stock solution of 50 mM but was dissolved into 1:1
DMSO/Ethanol because of solubility issues. Cyproterone Acetate (Sigma-Aldrich) was diluted
with 100 % ethanol and used at a 10 uM concentration. All stock solutions were diluted to final
concentrations using the dilution fluid provided in each kit. All tests were performed with
negative controls on the same plate and contained media alone and media containing the same
amount of ethanol utilized in the stock solutions. All assay control results were in accordance
with the stated technical performance specifications.

Mass Spectrometry
LC-MS/MS analysis of the steroid hormones were carried out using a Shimadzu Nexera UPLC
device coupled (Shimadzu Corp, Kyoto, Japan) to ABSciex (Foster City, CA) 5500 Hybrid
Triple Quadrapole Linear Ion Trap Mass Spectrometer operating in multiple reaction monitoring
mode. Nitrogen produced by a high-purity nitrogen generator (PEAK Scientific Instruments Ltd,
Chicago, Ill) was used as curtain, nebulizer and collision gases. Unit mass resolution was set in
both mass-resolving quadrupole Q1 and Q3 Ionization of the analytes were carried out using an
APCI source. Multiple MRM transitions were selected for each analyte to eliminate ambiguity in
analyte identification. For all steroids other than AED, 25 microliters of the media was directly
injected onto a 2.1 x 50mm 2.6 μm C18 Reverse Phase column (Phenomenex) and was separated
via a linear gradient of water:methanol 98:2 (Solvent A) to methanol:water 70:30 (Solvent B).
Both solvents contained 5mM ammonium formate with 1% formic acid. Separation of 17α-AED
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and 17β-AED was carried out using 2.1 x 150 mm 2.6μm C18 Reverse Phase column
(Phenomenex) and was separated using same Solvent A as above and 98:2 methanol: water with
5mM ammonium formate and 1% formic acid as Solvent B. Steroid hormones were detected
using precursor-product MRM pairs are as follows; DHEA (271-213, 271-197), Androstenetriol
(307-158, 307-254), Androstenediol (291-95, 291-159, 291-255), Testosterone (289-97, 289109), Androstenedione (287-97, 287-109), 17β-estradiol (273-107, 273-135, 273-77). Where
there were multiple transitions, the dominant peak was used in the analysis. All analytes
demonstrated a minimal limit of detection of at least 0.6 nM.

Cellular Uptake of Androstene Hormones and Normalization of Transactivation Assay Results
It was relevant to determine the relative uptake of each androstene hormone in the Indigo
Assay System. Cells and cell medium utilized in the assays were provided by the manufacturer
(Indigo Biosciences). The following components were found to be below the limit of detection in
the cells and cell medium: DHEA, 17β-estradiol, androstenedione, testosterone, 17α-AED, 17βAED and 17β-AET. LCMS data was utilized as a ratio between the background subtracted
signal (area under the curve of the LCMS trace) at time zero and 24 hours for each analyte
investigated. The ratios were then utilized to create normalization factors for the cellular uptake
of 17α-AED, 17β-AED and 17β-AET as compared to DHEA. The normalization factors were:
DHEA: 1, 17α-AED: 1.71, 17β-AED: 1.85, 17β-AET: 2.40, respectively. Background activity
due to cells, media and vehicle were subtracted before the data were normalized.
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Metabolism of Androstene Hormones
The cell medium was analyzed before and after incubation with assay cells. Mass
Spectroscopy was utilized to detect androstenedione, 17β-AED, 17α-AED and 17β-AET,
testosterone and 17β-estradiol that were expressed in the medium. Approximately 9% of DHEA
was metabolized to 17β-AED after a 24 hour incubation with assay cells. No other DHEA
metabolites were detected. Mass spectroscopy did not detect any metabolites of the other
androstene hormones in the media after a 24 hr incubation period. The Mass Spectrometry data
show that DHEA was minimally metabolized to 17β-AED in this cell construct, but not to
testosterone or 17β-estradiol (Methods 2.3.2). 17β-AED, 17β-AET and 17α-AED were not
metabolized.

Statistical Analysis
All statistical analyses were performed using SigmaPlot version 12(SSI, San Jose, CA, USA).
Hormone EC 50 level and the estrogen receptor alpha activation statistical analyses were
performed with a student's t test while all other hormone activation statistical comparisons were
performed with a one-way ANOVA. p value levels < 0.05 were considered significant. Statistics
on test groups were done before normalization to cellular uptake and were performed between
test groups and controls.

Results and Discussion
Androstene hormone structures
The hormones that were used in this study are listed in Figure 1. The structures demonstrate
the similarities and unique characteristics of each androstene hormone. The main differences are
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the orientation of the hydroxyl group at position C17 for 17α-AED and 17β-AED, the orientation
and position of the hydroxyl group at position C7 for 17β-AET, and the ketone group at position
17 for DHEA. 17α-AED and 17β-AED are chemically identical except for the placement of the

Figure 1. The structures of the Androstene Hormones
The androstene hormones are shown with the Δ5 cycloperhydrophenanthrene ring. All
steroids have a C3 hydroxyl group in the (β) beta position. The C7 hydroxyl group of
Androstenetriol is in the β-position. The C17 hydroxyl of Androstenediol epimers are in either
the (α) alpha or (β) beta position.
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hydroxyl group in relation to (above or below) the Δ5 cycloperhydrophenanthrene ring. All
adrenal hormones in this study, with the exception of DHEA, possess hydroxyl groups in the C3
and C17 position with 17α-AED having the C17 hydroxyl group in the (α) position. This
position at C17 results in remarkable biological actions [154][160] while the hydroxyl group at
C3 was shown not to influence the biological activity [177].

Androstene Hormone Activation of the Human AR receptor
The data demonstrate that both the orientation of the hydroxyl at position C17 and the
addition of the hydroxyl at position C7 affected the ability of 17β-AED, 17β-AET and 17α-AED
to activate the human AR construct (Figure 2). The AR receptor construct contains a luciferase
reporter gene that is functionally linked to an AR responsive promoter. The luciferase reading is
utilized as a surrogate measure for AR binding. The EC 50 was calculated for testosterone as the
50% activation point. EC 50 values for the androstene hormones and testosterone were calculated
(Table 1.) and compared utilizing the ratio of the androstene hormone EC 50 to testosterone EC 50
(Relative Androgenicity). All of the androstene hormones tested showed a significant (p<0.001)
reduced androgenicity when compared to testosterone (Table 1). 17β-AED had only 1/5th the
ability of testosterone to activate the androgen receptor. Changing the orientation of the C17
hydroxyl group on 17α-AED resulted in a further reduction to 1/60th the activity as compared to
testosterone. Addition of the hydroxyl group to the C7 position further reduced the ability to
activate the human AR construct to 1/1326th as that of testosterone. The androstene hormone
activation of the human AR was rank ordered based on strength of activation. The rank order
was: 17β-AED>>17α-AED>>>17β-AET (Figure 1). DHEA binding to the AR receptor was
excluded from these experiments since its androgenicity has been reported previously [175].
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Figure 2.

Androstene Hormone Activation of the Human Androgen Receptor

Reporter cells were treated with 17α-AED or 17β-AED or 17β-AET (n=3) at each
concentration, incubated for 24 hours and then assayed for luciferase activity. Androstene
hormone activity was normalized to cellular uptake (Methods). Error Bars, ± 1SD. Statistical
significance, p <0.001 versus androstene hormone metabolites in the same concentration group
(¤), p<0.001 versus androstene hormone metabolites in the same concentration group (*).
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Table 1. Relative Androgenicity of Androstene Hormones
Hormone
Testosterone
Δ5-androstene-3β, 17β-diol
Δ5-androstene-3β, 17α-diol
Δ5-androstene-3β, 7β, 17β-triol

EC 50 (nM)

Androgenicity

0.35
1.8
21
464

1
1/5
1/60
1/1326

p Value

1
<0.001
<0.001
<0.001

The EC 50 was calculated as the 50% activation point. The androgenicity is the testosterone EC 50 divided by the androstene hormone EC 50 . This
data does not normalize the cellular uptake of androstene hormones.

Androstene Hormone Activation of the human ERβ and ERα receptors
The data demonstrate that both the orientation of the hydroxyl at position C17 and the
addition of the hydroxyl at position C7 affected the ability of DHEA, 17β-AED, 17β-AET and
17α-AED to activate the human ERβ construct (Figure 3). The ER receptor construct contains a
luciferase reporter gene that is functionally linked to an ER responsive promoter. The luciferase
reading is utilized as a surrogate measure for ER binding. The EC 50 was calculated for 17βestradiol as the 50% activation point. EC 50 values for the androstene hormones and 17β-estradiol
were calculated (Table 2) and compared utilizing the ratio of the androstene hormone EC 50 to
17β-estradiol EC 50 (Relative Estrogenicity). All of the tested androstene hormones demonstrated
a significantly (p<0.001) decreased estrogenicity compared to 17β-estradiol (Table 2.). 17β-AED
had only 1/282 the ability of 17β-estradiol to activate the ERβ. The orientation change of the
hydroxyl group at position C17 of 17β-AED to the(α) position resulted in 17α-AED possessing
1/7609th the ability of 17β-estradiol to activate the ERβ receptor as 17β-estradiol. This
represents a drastic decrease in estrogenicity from the 17β-AED epimer. The presence of the
hydroxyl group at C7 of 17β-AET resulted in 1/587th the ability to activate the ERβ. DHEA,
with a ketone group in the C17 position, possessed 1/3543rd the ability to activate the ERβ.
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The rank order of androstene hormone activation on the human ERβ receptor can be
displayed as follows: 17β-AED >17β-AET >DHEA>17α-AED (Figure 3).

Figure 3. Androstene Hormone Activation of the Human Estrogen Receptor Beta
Reporter cells were treated with 17α-AED or 17β-AED or 17β-AET or DHEA (n=3) at each
concentration, incubated for 24 hours and then assayed for luciferase activity (n=3), incubated.
Androstene hormone activity was normalized to cellular uptake. Error Bars, ± 1SD. Statistical
significance, p<0.001(¤) versus androstene hormone metabolites in the same concentration
group, p< 0.001(*) versus lower reacting androstene hormones in the same concentration group
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These androstene hormones also specifically activated the human ERβ receptor and
demonstrated the crucial effect of the (β) C17 hydroxyl group. 17β-AED and 17α-AED activated
the ERβ receptor 2 and 3 orders of magnitude lower respectively than 17β-estradiol (Table 2).
The 17β-AED demonstrated an estrogenicity of 1/1176 when assayed on the human ERα.
Activation of the ERα receptor by 17β-AED did not become apparent until the concentration

Figure 4. 17β-AED Activation of the Human Estrogen Receptor Alpha
Reporter cells were treated with 17β-AED (n=3), incubated for 24 hours, and then assayed
for luciferase activity. 17β-AED activity was normalized to cellular uptake, Error Bars, ± 1SD.

reached 25 nM (Figure 4) which was 3 orders of magnitude lower than 17β-estradiol further
demonstrating the weak estrogenicity displayed by these hormones at the level of the ER
receptors. Finally, it should be noted that the androstene hormones only weakly activated the AR
receptor and were even weaker activators of the human ER receptors.
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Table 2: Relative Estrogenicity of Androstene Hormones
Hormone
17β-estradiol
Δ5-androstene-3β, 17β-diol
Δ5-androstene-3β, 7β, 17β-triol
DHEA
Δ5-androstene-3β, 17α-diol

EC 50 (nM)

Estrogenicity

0.046
13
27
163
350

1
1/282
1/587
1/3543
1/7609

p Value

1
<0.001
<0.001
<0.001
<0.001

The EC 50 was calculated as the 50% activation point The estrogenicity is the 17β-estradiol EC 50 divided by the androstene hormone EC 50. This
data does not normalize the cellular uptake of androstene hormones.

Androstene Hormones Activation of the Human Glucocorticoid (GR) Receptor
17β-AED, and especially 17β-AET are known to produce significantly affect glucocorticoid
activity in vivo [92][78][91]. Therefore, the human GR construct response to 17β-AED, 17βAET, DHEA and 17α-AED alone and in combination with dexamethasone was evaluated. The
results showed dexamethasone alone activated the human GR receptor while17β-AED, 17βAET, DHEA, and 17α-AED alone were negative at all concentrations tested (Figure 5).

36

Figure 5. Dexamethasone or Androstene Hormone Activation of the Human
Glucocorticoid Receptor
Reporter cells were treated with dexamethasone or androstene hormones alone (n=3),
incubated for 24 hours, and then assayed for luciferase activity. Androstene Hormones are:
DHEA, 17β-AED, 17α-AED and 17β- AET. Error Bars, ± 1SD.
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The human GR receptor was then tested for activity with androstene hormones in the
presence of dexamethasone. Unexpectedly, at supra-pharmacological levels of dexamethasone
there was a considerable activation of the human GR receptor by 1 µM of each of the androstene
hormones, which was greater than with dexamethasone alone with a higher activity when
dexamethasone concentration was increased from 333pM to 1000 pM (Figure 6).
The rank order of activation of the dexamethasone-bound human GR receptor in the presence
of the androstene hormones is: 17β-AET>17β-AED>17α-AED>DHEA. These data demonstrate
that the C7 hydroxyl present in 17β-AET produced the strongest activation of the
dexamethasone-bound human GR. The (β) C17 hydroxyl of 17β-AED produced a stronger
activation than did the (α) C17 hydroxyl of 17α-AED. Thus, while 17β-AED and 17α-AED
produced unique activation of the dexamethasone-bound human GR, the effect of the C17
hydroxyl group conformation was less apparent. DHEA, which has the keto group in the C17
position, possessed the least ability to activate the dexamethasone-bound human GR.
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Figure 6. Androstene Hormones and Dexamethasone Activation of the Human GR
Receptor
Reporter cells were treated with dexamethasone alone or a combination of dexamethasone
and androstene hormone, incubated for 24 hours, and then assayed for luciferase activity.(n=3).
Androstene hormone activity was normalized to cellular uptake. Error Bars, ± 1SD. Statistical
significance, p is at least <0.05 from other androstene hormone metabolites within the
dexamethasone concentration treatment group (¤), p is <0.05 versus control (*), p is <0.05 from
333pM dexamethasone treatment group (●).
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We next tested these effects with the dexamethasone inhibitor, cyproterone acetate to see if
we could reduce or eliminate the dexamethasone and androstene hormone activation of the
human GR receptor. Cyproterone acetate was selected as the inhibitor because of its unique
glucocorticoid receptor inhibiting properties [178]. Cyproterone effectively inhibited the
activation of the human GR receptor by dexamethasone (Figure 7). Cyproterone acetate at a
concentration of 10uM was tested in the presence of the androstene hormones alone (1.0 uM)
and there was no activation detected (data not shown). Androstene hormones, however in the
presence of cyproterone and dexamethasone exhibited different levels of activation that were
significantly increased above the dexamethasone/cyproterone alone controls (Figure 7). These
results are of particular clinical significance because it demonstrates that high dose
dexamethasone alters the human GR receptor to interact with other biologically active hormones
at the receptor level. Importantly, dexamethasone, is known to cause adverse effects in humans
[179].
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Figure 7. Androstene Hormone and Dexamethasone Activation of the Human GR
Receptor in the presence of Cyproterone Acetate
Reporter cells were treated with dexamethasone and cyproterone acetate alone
or androstene hormones with dexamethasone and cyproterone acetate (n=3), incubated for 24
hours, and then assayed for luciferase activity. Androstene hormone activity was normalized to
cellular uptake. Error Bars ± 1SD, Statistical significance, p is <0.05 from other androstene
hormone metabolites within the dexamethasone treatment group (¤), p<0.05 from
controls (*).
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The rank order of activation of the dexamethasone/cyproterone acetate-bound human GR in
the presence of these androstene hormones is: 17β-AET>17β-AED>17α-AED>DHEA. This
rank order of activation on the inhibited human GR was the same as that of the uninhibited
human GR indicating that the interaction of the androstene hormones and the
dexamethasone/cyproterone-bound human GR was not disrupted. Because cyproterone acetate is
a passive inhibitor of the human GR receptor and opposes dexamethasone through an
overlapping steroid scaffold mechanism, this suggests that the androstene hormone activation is
mediated by an interaction that occurs outside the dexamethasone/cyproterone acetate-bound
complex [178]. Additionally, the presence of dexamethasone-bound human GR is required to
observe activation by the androstene hormones while cyproterone acetate alone does not mediate
this effect. Together these data suggest an indirect activation of the ligand-bound human GR
receptor by 17β-AET, 17β-AED, 17α-AED and DHEA.

Summary
These results indicate that the position of the hydroxyl group at C17 and/or the addition of
the hydroxyl group at position C7 significantly affected the ability of 17β-AET, 17β-AED, 17αAED and DHEA to interact with the human estrogen, androgen and ligand-bound GR receptors.
17β-AET, 17β-AED, 17α-AED and DHEA were shown to interact either directly or indirectly
with the human (AR, ER) and GR respectively. Importantly, 17β-AET, 17β-AED, 17α-AED and
DHEA were shown to possess weak androgenicity and even weaker estrogenicity at the receptor
level. Clinically, this is beneficial because the biological effects can be realized without
unwanted androgenic or estrogenic effects.
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In stark contrast to the minimal receptor activation of AR, ER and GR, these same
androstene hormones produce striking biological effects in vitro and in vivo which have been
attributed to activity with the AR, ER or GR receptors. Clearly, these effects may not be
mediated by the direct androstene hormone interaction with the human AR, ERα, ERβ and GR
receptors. Indeed, the biological mechanism, may not require AR or ER receptors to achieve
significant effects [155][180]. Furthermore, the interaction with dexamethasone is indirect,
occurs at high doses and is not abolished by cyproterone acetate. Taken together, the data shows
that interactions of 17β-AET, 17β-AED, 17α-AED and DHEA with the human AR, ERα, ERβ
and GR receptors are directed by the structure-activity of these androstene hormones with
minimal androgenic, estrogenic or glucocorticoid effects and accentuates the need to further
uncover the implied yet unidentified main mechanism (s) of action of these important adrenal
hormones.
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CHAPTER 3: Androstene Hormone Epimers Regulate ER Stress and Core Regulatory Genes in
Human T98G Glioma Cells.

Introduction
High grade gliomas represent approximately 50% of the primary central nervous
system(CNS) tumors with 15,000 cases diagnosed in the United States each year [181].Grade IV
glioblastomas (Glioblastoma Multiforme) are World Health Organization(WHO) classified as
astrocytic neoplasms derived from the glial lineage that have progressed from Grade III(high
proliferation) to Grade IV(necrotic tissue and/or angiogenic activity)[182][183][184][185]. The
mean life expectancy of patients with Glioblastoma Multiforme is only 1 year from the time of
initial diagnosis and only several months after progression [186]. The traditional therapy for
these aggressive tumors is surgical resection followed by external beam radiation and/or
chemotherapy, however, these treatments are considered palliative with only a very low survival
rate. Temozolomide, an oral alkylating agent that enters the CNS, is the most commonly used
chemotherapy treatment alone or in combination with compounds known to induce cell death
[187][188]. Temozolomide, an oral alkylating agent, however, only improves the lifespan of
malignant glioma patients by 2-3 months [187]. A major obstacle to complete tumor resection is
the high invasiveness of the tumors [8].
Human derived T98G cells are a well characterized in vitro model of glioblastoma [189].
These cells were obtained from a 61 year old male and became spontaneously polyploid through
culture passage [190]. T98G glioblastoma cells have been utilized as a model system for
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targeting

Glioblastoma

Multiforme

pathways

[191].

T98G

cells

contain

functional

PDGF(Platelet Derived Growth Factor) receptors that can induce a malignant phenotype with
sufficient stimulation [192][193]. T98G cells contain multiple mutations that have contributed to
their tumorigenic properties. These mutations include a homozygous mutation for p53,
CDKN2A deletion and PTEN mutation [193][194]. Transformation of T98G cells by PDGF
combined with the loss of tumor suppressor activity is associated with three signaling pathways
that are crucial in Glioblastoma [193].
Δ5-androstene-3β, 17α-diol (17α-AED) has been shown to produce definitive type II
programmed cell death in T98G cells (Figure 8) [157]. The mechanism whereby 17α-AED
induces oncophagy in T98G cells has previously been identified and described [195][196]. Δ5androstene-3β, 17β-diol (17β-AED) is the epimer of 17α-AED. These naturally produced adrenal
hormones are chemically identical and differ only in the stereoisomeric position of the hydroxyl
group located at carbon 17 of the steroid ring structure. 17β-AED, in opposition to 17α-AED,
does not produce cell death in T98G Glioblastoma cells (Figure 8) [196]. 17β-AED, in fact,
promotes significant biological effects including the enhancement of the immune system
[81][197] even in the presence of glucocorticoids [112][109] and provides protection against
lethal radiation [198]. The relationship of chemical structure to biological
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Figure 8: Contrasting Effects on Cell Morphology of T98Glioma cells treated with 17αAED or 17β-AED. Prior confirmation of autophagy in cells treated with 9.5 uM of 17α-AED
was performed with electron microscopy [16]. Cells were stained with hematoxylin and eosin
and visualized with light microscopy at 100x. Left panel demonstrates autophagy induced by
17α-AED while the right panel demonstrates the lack of apoptosis or autophagy in 17β-AED
treated cells.

function is shown in Figure 9 and Table 3 lists the opposing biological functions of 17β-AED
and 17α-AED.
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Figure 9: Structure-function relationship of the 17 hydroxyl position of the chemically
identical androstenediol epimers, 17α-AED and 17β-AED results in opposing biological
functions. The 17α-AED results in oncophagy (target cell specific cell death by apoptosis or
autophagy) while the 17β-AED result in Immune Upregulation (adapted from Loria and Graf
(2012).

Many large-scale investigations into complex human disease have been performed and
genome wide analysis of RNA expression is a common way to investigate complex human
disease. It has been stated that the major challenge of these investigations is to gain relevant
biological insight into these diseases [199]. 17α-AED and 17β-AED are chemically identical,
produce either cell survival or irreversible death, and the biological actions of 17α-AED have
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been partially identified. Clearly these epimers are ideal for monitoring the “mirror” effects
observed in human Glioblastoma cells. Thus, we utilized these hormones, signal targeting
microarray genes and Ingenuity IPA® networking software to demonstrate that these
stereoisomers regulate core transcriptional regulators and influence critical signal transduction
pathways that are critical for the death or survival of Glioblastoma.
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TABLE 3: Biological Function of 17α-AED and 17β-AED
Hormone

Model
Type

17α-AED

In vitro

Cell
Type(s)
ZR-75-1 MCF-7

Biological

Function(s)

1) Inhibition of DNA Synthesis
2) Androgen and Estrogen independent
inhibition of tumor cell proliferation

References

(Huynh et al., 2000)

3) Combined treatment of 17α-AED and
17β-AED potentiated the effect of 17α-AED

In vitro

T98G U937

1) 17α-AED induces autophagy in the
glioblastoma cell line(T98G)

(Loria and Graf, 2012)

2) 17α-AED induces apoptosis in the
myeloid cell line(U937)
3) Type of cell death induced by17α-AED is
determined by the target tissue
In vitro

T98G
U87MG
U251MG
LN-18
\N-229
LN-Z308

1) Autophagy induced specifically through
PERK/CHOP/ GRP78/elF2α /BECLIN/LC3
signaling and not through IRE1 or ATF6

(Loria et al., 2012)(Jia et al., 2010)

2) Inhibition of elF2α in T98G cells by
introduction of elF2αS51A dominant
negative inhibited the induction of
autophagy by 17α-AED
3) ER stress is linked to 17α-AED induced
autophagy by PERK/elF2α signaling
In Vitro

MCF-7 MDA231 T47D
TTU-1

1) Enhanced radiation cytotoxicity and
autophagy induction in human breast cells

(Loria et al., 2012)

2) Estrogen independent inhibition of tumor
cell proliferation
3) Autophagy induced through
PERK/CHOP/elF2α signling
In vitro

T98G

1) The position of the hydroxyl located at
carbon-17 of the chemically identical
stereoisomers of androstenediol dictates the
biological effect.
2) The 3-hydroxyl position was found to not
influence biological effects.
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(Graf et al., 2009)

TABLE 3: Biological Function of 17α-AED and 17β-AED (Continued)
17β-AED

17α-AED/
17β-AED

In vitro

HL-60 P388D1

1) Does not inhibit DNA synthesis at
concentrations that produced
irreversible cell death with 17α-AED
2) High doses did decrease DNA
synthesis

In vivo

ZR-75-1 MCF-1

1) 17β-AED shown to increase the
proliferation of ZR75-1 and MCF-7
cells

In vivo

CD-1 Mice

1) Protection from lethal infections of
Pseudomonas aeruginosa and
Enterococcus faecalis

In vivo

Male Sprague
Dawley Rats

1) KLF6, BCL2, p53 upregulated by
17β-AED leading to downregulation of
iNOS and

(Kiang et al., 2007)

In vivo

CD-1 Mice

1) In wound healing: countered the
suppressive effect of restraint on
MCP-1 and IL-1 expression in mice

(Head et al., 2006)

Ex-vivo

Murine
Lymphocytes

1) Minimally counteracts
hydrocortisone suppression of IL-2/IL3 production and cell proliferation and
does not cause splenocyte
proliferation

(Padgett and Loria, 1994)

In vitro

Assay Cells

1) 17α-AED and 17β-AED differentially
and directly activate human estrogen
alpha, estrogen beta, androgen and
indirectly activate glucocorticoid
constructs at the level of the receptor
in a whole cell construct with markedly
decreased androgenicity and
estrogenicity

[200]
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(Huynh, P, Loria, R.M, 1997)

(Poulin, R., Labrie, F.,
1986) (Hackenberg, R. et al., 1993)

(Ben-Nathan et al, 1999)

Methodology
Cell culture
T98G Glioblastoma cells were culture in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum and nonessential amino acids as adherent monolayers
at 37oC, passed biweekly with trypsin in the absence of antibiotics. All tissue culture reagents
and supplements were obtained from Invitrogen (Carlsbad, CA). The human T98G line was
acquired from the American Type Culture Collection (Manassas, VA) and maintained by the
Neuro-Oncology Research Group at the Virginia Commonwealth Medical Center, Richmond,
VA.

Androstene Hormone Controls
17α-AED and 17β-AED are chemically identical and the control was running both
hormones in parallel. The only difference between these hormones is the stereoisometric position
of the hydroxyl located at the C17 position (Figure 9). Therefore, qPCR confirmation was not
necessary as only those genes displaying opposite regulation were considered in the analysis.

The Human Signal Transduction Pathway Finder Microarray
OligoGEArray, catalogue number OHS-014, (SuperArray Bioscience Corporation,
Frederick, MD) was utilized to identify genes regulated by 17α-AED and 17β-AED in T98G
cells. After an overnight incubation, cell medium was replaced and the T98G Glioma cells
(1x104/well) were cultured in a 6-well, tissue culture plate in the presence of 9.5 uM 17α-AED or
17β-AED (provided by Dr. Loria). This concentration is the IC 50 of 17α-AED treated T98G
cells. Cells demonstrated morphology consistent with prior studies. Control wells were treated
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with vehicle (50% PEG 400/50% ethanol). After a 20 hour incubation, the medium was removed
and RNA was extracted from cells utilizing an RNAeasy kit (Qiagen, Valencia, CA) and
quantitated spectrophotometrically. 1 ug/ml RNA was utilized with 3 uL GEAprimer Mix and 6
ul H 2 O in the annealing mixture for probe synthesis. This mixture was heated at 70oC for 3 min
then cooled to 42oC and then incubated at 42oC for 2 min. Labeling mix was then prepared by
mixing 4ul of 5X GEA labeling Buffer, 3ul of [a-32P] dCTP (10mCi/ml), 1ul RNase inhibitor,
1ul Reverse transcriptase (50U/ml) and 1ul of RNase free H 2 O. The labeling mix was then added
to the RNA and the labeling reaction was run for 25 min at 42oC. The reaction was stopped with
2 ul of stop solution then denatured with 2ul of denaturing solution at 68oC for 20 min after
which probe neutralization was performed with 20 ul of neutralization solution at 68oC for 10
min. Labeled probes were mixed with hybridization buffer and added to a prehybridized
membrane and incubated overnight at 60oC. The hybridized membrane was washed 2x with
SSC, 1% SDS for 10min at 60oC then washed once with 0.1x SSC, 0.5% SDS for 10 min at 60oC
(Figure 10).
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Figure 10: Human signal Transduction Pathway Finder Microarray
Human T98G Glioma cells were treated with vehicle or neuro-steroid for 20h. Total RNA
was used to generate cRNA which was them used to probe the microarrays which contain DNA
oligos from genes related to cell stress, cell toxicity, drug resistance and drug metabolism. Spots
that are contained in the heavy circles represent housekeeping genes (β-actin, β2-microglobulin,
ribosomal protein 27a, etc.) used to normalize the data. The light circle represents an internal
control for orientation.
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IPA Network Generation and Analysis
Network Generation
An Ingenuity IPA® core analysis was performed where the identified target genes overlaid onto
a global molecular network developed from information contained in the IPA database. The
Ingenuity Knowledge Base Includes: Data Sources scanned included Ingenuity expert findings®,
mi records, TaRbase, TargetScan Human, BIND, BIOGRID, Cognia, DIP, INTACT,
Interactome studies, MINT, MIPS, ClinicalTrials.gov, GeneOntology, GVK Biosciences, Kyoto
Encyclopedia of Genes, miRBase and the Obesity Gene Map.

Network Score Statistics
The network score is a statistical numerical value used to estimate how well the network
eligible genes match the Ingenuity Knowledge Base genes. The score takes into account the total
number of network eligible molecules, network size, and the total number of possible associated
molecules in the Ingenuity Knowledge Base. The Network Score is based on the hypergeometric
distribution and is calculated with the right-tailed Fisher's Exact Test. For example, a network of
35 molecules has a Fisher Exact Test result of 1x10-8. The network’s Score = -log (Fisher's Exact
test result) = 8. This is interpreted as there is a 1 in a 100 million chance of obtaining the 35
molecule network containing network eligible molecules randomly that could be in networks
generated from the Ingenuity Knowledge Base.
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Results and Discussion
The Human Signal Transduction Pathway Finder Microarray
Microarray results were imaged on a phosphoimager. The acquired images were
extracted and converted into raw signals using GEArray ScanAlyze software. The procedure is
found at:(http://www.sabiosciences.com/manuals/GEArrayAnalyzerTutorial.ppt#278, 27, Chart).
Probe sets were compared and normalized to β-actin controls (Figure 11).
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Figure 11: Contrasting Effects on Gene Expression in T98Glioma cells treated with 17αAED or 17β-AED. A) Decreased gene expression in T98G cells treated with 17α-AED. Green
marks below the vertical represent genes in T98G cells treated with 17α-AED that have a greater
than 5-fold decrease in expression as compared to T98G cells treated with vehicle. Data
normalized to β-actin gene expression. B) Same as in A, however T98G cells were treated with
9.5 uM of 17β-AED. Numerous genes show a more than 5-fold increase in expression as
indicated by red marks above the vertical.
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Network Analysis
All 26 target gene probesets were mapped to their corresponding gene in the IPA
Knowledge Base through the GenBank ID number. The IPA core analysis yielded a total of five,
35 molecule networks which were based on a score. The score takes into account the total
number of network eligible genes, network size, and the total number of possible associated
molecules in the Ingenuity Knowledge Base. The network scores for the network analysis are as
follows network 1: (score: 16), network 2: (score: 12), network 3: (score: 12), network 4: (score:
10), network 5: (score: 1). It should be noted that network 5 (1 in 10 chance of occurring
randomly) is not statistically significant while the first 4 networks are extremely statistically
significant. Network 1 has a 1 in 10 zillion chance of being random, networks 2 and 3 have a 1 in
1 trillion chance of being random and network 4 has a 1 in 10 billion chance of being random.
Target Genes
The term "Target Gene(s)" refers to the total geneset whose expression 1) was regulated
down (negative), at a minimum of 5 fold by 17α-AED and/or regulated up (positive), at a
minimum of 5 fold by 17β-AED and 2) resulted in a total difference in gene expression that is, at a
minimum, an order of magnitude) between 17α-AED downregulated and 17β-AED upregulated
expression of that gene. Because 17α-AED and 17β-AED are chemically identical this 10 fold or
greater significance indicates that this expression may be related to the opposing biological
functions of survival or irreversible cell death. We have identified 26 target genes in human T98G
glioma cells (Table 4).
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TABLE 4: 17α-AED/17β-AED Target Genes in T98G glioma cells
GENE

GENE BANK
ID

DESCRIPTION

17α-AED

17β-AED

BMP2

NM_001200

bone morphogenetic protein
2

<5

>5

BRCA1
CCL2

NM_007294
NM_002982

breast cancer 1, early onset
chemokine(C-C motif)
Ligands 2

<5
<5

>5
>5

CTSD

NM_001909

cathepsin D

<5

>5

CDKN1A

NM_000389

<5

>5

CDKN2D

NM_001800

cyclin-depensdent
kinaseinhibitor 1A(p21,
Cip1)
cyclin-dependent Kinase
inhibitor 2D(p19, inhibits
CDK4)

<5

>5

CDK2
CSN2
EGFR

NM_001798
NM_001891
NM_005228

cyclin-dependent kinase 2
casein beta
epidermal growth factor
receptor

<5
<5
<5

>5
>5
>5

EGR1
GADD45A

NM_001964
NM_001924

early growth response 1
growth arrest and DNAdamage-inducible, alpha

<5
<5

>5
>5

GYS1

NM_002103

glycogen synthase 1(muscle)

<5

>5

HOXB1
ICAM1

NM_002144
NM_000201

homeobox B1
intercellular adhesion
molecule 1

<5
<5

>5
>5

IGFBP4

NM_001552

insulin-like growth factor
binding protein 4

<5

>5

IRF1
JUN
NAB2

NM_002198
NM_002228
NM_005967

<5
<5
<5

>5
>5
>5

NFKBIA

NM_020529

interferon regulatory factor 1
jun proto-oncogene
NGFI-A binding
protein2(EGR1 bindingprotein 2)
nuclear factor of kappa light
polypeptide gene enhancer in
B-cells inhibitor, alpha

<5

>5

ODC1
PMEPA1

NM_002539
NM_020182

ornithine decarboxylase 1
prostate transmembrane
protein, androgen-induced 1

<5
<5

>5
>5

TP53
TP53I3

NM_000546
NM_004881

tumor protein p53
tumor protein p53 inducible
protein 3

<5
<5

>5
>5

WNT1

NM_005430

wingless-type MMTV

<5

>5
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General Discussion
Tumor cells are embedded in a hostile environment that is constantly challenged by
chronic metabolic stress conditions that favor the activation of adaptive mechanisms in response
to stress which includes autophagy [201][202]. The surrounding environment can influence the
type and amount of protein that need to be folded in the ER. Unfolded protein responses (UPR)
are initiated when misfolded proteins are sensed in the endoplasmic reticulum (ER). Previously it
was shown that the same agent, the neurosteroid, 17α-AED can induce irreversible type I cell
death (apoptosis) in myeloid cells and type II cell death in human glioma cells (autophagy)
[154].
It was shown that 17α-AED-induced autophagy in T98G cells occurred through a
specific partial unfolded protein response (UPR) [161] where the mechanism appeared to evolve
from PERK activation and proceed to the phosphorylation of the eukaryotic translation initiation
factor 2α. Specifically, elF2α phosphorylation was shown to induce CHOP (CCAAT/enhancer
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Figure 12. General Mechanism of Autophagy Induction by 17α-AED

binding protein homologous protein (CHOP) and the ER chaperone proteins such as glucoseregulated protein of 78kDa (GRP78)) [161]. The response was also shown to be independent of
the double stranded RNA-activated protein kinase (PKR) and the general control nonderepressable 2 (GCN2) protein kinase [161]. These molecular events ended in the induction of
beclin-1 and microtubule light chain 3 (LC3) cleavage resulting in irreversible autophagy. Thus,
in TG98 Glioblastoma 17α-AED induces an unfolded protein response through PERK activation
with resultant autophagy (Figure 12). 17β-AED, the chemically identical epimer, appears to
produce a different response that results in survival.
Autophagy ensues when beclin-1 forms a complex with Vps34 (PI3KClass III) [203].
BCL-2 prevents autophagy by forming a mutually exclusive complex with beclin-1 through the
BH3 domain and inhibiting beclin-1 [204]. BCL-2 is an anti-apoptotic member of the BCL-2
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family which binds to the outer membrane of the mitochondrion and serves to sequester BH3only proteins through direct binding. BCL-2 acts as a shield against these BH-3 only proapoptotic agents which attack and destabilize the mitochondrion [205]. When BCL-2 cannot
effectively bind beclin-1 then beclin-1 forms a complex with Vps34 (PI3KClass III) which
activates membrane nucleation with ensuing autophagy [203].
Network analysis revealed that breast cancer early onset (BRCA-1) and BCL2 were main
hubs that were directly associated in Network 1 (most significant) which demonstrate their main
role in T98G stress response directed by 17α-AED and 17β-AED. Network analysis also
demonstrated that GADD45 and IRF-1 were clustered together in network 4 while CDKN1A
was clustered in network 2. These observations indicate that while CDKN1A, GADD45 and
IRF-1 are BRCA-1 targets they are separated functionally from BRCA-1 by association with
different genes.
17α-AED induces CHOP which is known to downregulate BCL-2 expression [161][206].
17α-AED downregulated both BCL-2 and BRCA-1 suggesting that the biological response
initiated by 17α-AED extends beyond downregulation of BCL-2. Conversely, 17β-AED
upregulated both BCL-2 and BRCA-1. Overexpression of BRCA-1 was shown to produce an
apoptotic phenotype and correlated with GADD45 production [207]. 17β-AED upregulated
BRCA-1, CDKN1A, GADD45 and IRF-1 and did not produce cell death. These are target genes
that are associated with DNA repair, cell cycle regulation and immunity [208]. Upregulation of
these genes have been shown to be BRCA-1 dependent [209][210]. CDKN1A expression,
however, is not always obtained in the presence of BRCA-1 [211].
Recently, it was shown that BCL-2 co-localizes with BRCA-1 to the mitochondrial and
endoplasmic reticulum endomembranes [41]. BCL-2, while protective, will oppose genome
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stability by binding to and preventing nuclear localization of BRCA-1 which results in an
apoptotic phenotype [41]. BCL-2 will preferentially bind to Beclin-1 and inhibit autophagy
[212]. Subsequently, the GADD45, CDKN1A and IRF-1 upregulation by 17β-AED indicates
nuclear BRCA-1 activity despite upregulated BCL-2. 17α-AED directs a downregulation of
BRCA-1 and BCL-2, thus targeting the beclin-1/Vps34 interface and irreversible autophagy
(Figure 13). BRCA-1 is considered a tumor suppressor. Downregulation of BRCA-1 with
activation of irreversible cell death demonstrates that while BRCA-1 is involved in these
processes it is not required to achieve cell death.
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Figure 13. Stress Induced Responses Directed by 17α-AED and 17β-AED
A) Specific 17α-AED-directed, PERK activated stress response leading to autophagy B) BRCA1 and BCL-2 are induced by 17β-AED leading to autophagy inhibition, DNA repair, growth
control, immune response and survival. Double slash // indicates a complex.
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The regulated expression of CDKN1A by BRCA-1 has been shown to occur in p53 dependent
and independent manner. p53-independent induction of CDKN1A may occur through an
interaction that occurs through a binding interaction of BRCA-1 with C-terminal binding protein
(CtBP) and retinoblastoma binding protein 8 (CtIP) [213]. This interaction normally inhibits the
activation of BRCA-1 but in the presence of stress BRCA-1 is released from this inhibitory
interaction to activate gene transcription [213]. In another study, it was shown that BRCA-1
augments the p53 transcription factor but selectively induces genes involved in DNA repair and
arrest of the cell cycle but not genes that direct apoptosis for target gene induction [214]. The
absence of apoptosis from 17β-AED induced CDKN1A suggests that the main function of 17βAED in T98G cells depends on BRCA-1 in a p53-dependent way (Figure 14).
Further support is demonstrated by the 17β-AED directed upregulation of BRCA-1, p53,
GADD45 and TP53I3 (PIG3) which indicates the stabilization of p53 with expression of DNA
repair genes. Importantly, this is occurring in the presence the p53 dual mutation that is present
in T98G cells [193][194]. Interestingly, these observations may indicate a role for 17β-AED in
BRCA-1 mediated tumor suppression.
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Figure 14. BRCA-1 directed, p53 dependent transcriptional response induced by 17βAED.
A) BRCA-1 directed, p53 independent transcriptional response induced by stress. B) BRCA-1
directed, p53 dependent transcriptional response induced by 17β-AED.

We show that 17β-AED and 17α-AED regulated p53 in an opposing manner). Network
analysis of 17β-AED and 17α-AED target genes demonstrated that AKT was the central
signaling hub of the top ranked network indicating its importance and significance. The Wnt
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pathway was previously shown to act in conjunction with AKT to stimulate phosphorylation and
inactivation of GSK3B [215]. 17α-AED downregulated WNT1 thus supporting activation of

Figure 15. Opposing Regulation of p53 Expression Induced by 17α-AED or 17β-AED
through WNT1, AKT and GSK3β.
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GSK3B. Additionally, activation of PERK by 17α-AED also supports the activation of GSK3B
kinase further reinforcing the reduction of p53 [216]. Conversely, 17β-AED upregulated p53 and
WNT1 and the latter is known to decrease the activity of GSK3B through canonical WNT
signaling [217]. Thus, this evidence suggests that 17β-AED opposes the action of 17α-AED by
influencing the expression of WNT1 and subsequently influencing the AKT/GSK3B axis
resulting in the opposing transcription of p53 (Figure 15).
Network analysis demonstrated that the target molecules of AKT in the dataset (BCL2,
BMP2, CCL2, CDK2, CDKN1A, CSN2, EGR1, and TP53) were inconsistent with predicted
findings for gene expression induced by 17β-AED and 17α-AED. Furthermore, the predictions
of AKT target molecules were also opposing demonstrating that AKT is modulated by both
steroids. It is important to mention that the PTEN tumor suppressor is mutated in T98G cells
[193]. This mutation is important twofold. First, PTEN is a tumor suppressor that induces
autophagy [218] and second, PTEN can do this by activating the PERK/elF2α independently of
its phosphatase activity [219]. This demonstrates that 17α-AED induces irreversible autophagy
through PERK and elF2α independently of PTEN. It is unclear at this point if the PTEN mutation
in T98G cells affects the BRCA-1 directed, p53 dependent response induced by 17β-AED.
An important observation from the microarray is that 17β-AED induced upregulation of
both CDKN2D and p53. A p53 core regulator complex composed of MDM2, p53, CDKN2A and
E2F was shown to regulate genes controlling G1-S and G2-M cell cycle arrest, apoptosis,
inhibition of angiogenesis /metastasis and DNA repair (Figure 16A) [220]. CDKN2A and/or
CDKN2D will bind to and inactivate MDM2, a ubiquitin ligase that will ubiquitinate p53
resulting in increased levels and stabilization of the p53 protein
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Figure 16: Core Regulatory Unit Governing Cell Cycle Arrest, Apoptosis, Inhibition of
Angiogenesis and Metastasis and DNA Repair
A) Normal Core Regulatory Unit B) T98G core regulatory unit disrupted by mutations in p53
and CDKN2A C) 17β-AED induced CDKN2D partially restructures the core regulatory unit D)
17α-AED downregulates p53 and CDKN2D disrupting the core regulatory unit leading to the
induction of irreversible autophagy.
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[221][222]. CDKN2A and/or CDKN2D complexes are positively regulated by E2F1[223].
CDKN2A is deleted in T98G cells which affects the CDKN2A/p53 axis as well as CDKN2A/Rb
axis (Figure 16B).
.

DNA damage will activate p53 but not CDKN2A/CDKN2D [ 224][225]. Thus, 17β-

AED and not DNA damage upregulated CDKN2D to restructure the p53 core regulatory unit
(Figure 16C). CDKN2A is associated with tumor suppressor functionality through p53
dependent apoptosis whereas CDKN2D is not [226][227]. However, p53-negative cell lines are
resistant to CDKN2D-induced growth arrest [225]. Furthermore, loss of CDKN2D in the
presence of functional CDKN2A results in tumors early in life [225]. Together, these
observations demonstrate that some functionality is restored to the p53 core regulatory unit
through CDKN2D. However, at this point it is unclear how the functionality is affected because
CDKN2A is deleted in T98G cells. In contrast to 17β-AED, 17α-AED downregulated p53 and
CDKN2D. These observations demonstrate that 17α-AED influences the p53, CDKN2D and
E2F core regulatory unit by downregulating p53 and CDKN2D while 17β-AED restructures this
core regulatory unit through upregulation of p53 and CDKN2D.
Free E2F is a link between p53 and the retinoblastoma tumor suppressor (Rb) [227]. The
cell cycle normally progresses when Rb is inactivated by phosphorylation that is catalyzed by
CDK-cyclin complexes [228][229]. Rb and E2F were associated with CDK2 (a target gene) in
the core network analysis. CDK2 is present within the CDK-cyclin complexes that drive the cell
through G1-S phases of the cell cycle. CDK2 is a central gene that is known to be necessary to
facilitate the hyperphosphorylation of the Rb pocket after a priming phosphorylation by CDK4/6
leading to the inactivation of Rb and the release of E2F and thus CDK2 is required for
inactivation of the Rb protein [227].
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17β-AED induces upregulation of CDK2 thus making it possible for the inactivation of
Rb through CDK2-cyclin complexes. In opposition to 17β-AED, 17α-AED downregulated
CDK2 and thus negatively influenced the primary phosphorylating complexes related to CDK2
that would both drive the cell through G1-S and inactivate Rb by phosphorylation. It has been
demonstrated that Rb-E2F is a rheostat that is modulated by phosphorylation thus playing an
integral part in the induction of autophagy [230][231]. Here, we show that 17α-AED induced
significant downregulation of CDK2, p53 and BCL2 transcription which is consistent with
inhibition of the cell cycle, activation of the Rb complex and the strong induction of autophagy
which was clearly demonstrated to occur (Figure 16D). Furthermore, it has been demonstrated
that Rb/E2F plays a direct role in the regulation of Hox genes [232]. The fact that HoxB1 was
identified as a target gene provides further support that RB/E2F is a target of 17β-AED and 17αAED.
Finally, free E2F produced through Rb phosphorylation has been shown to produce p53
dependent apoptosis mediated through CDKN2A and p53 independent apoptosis mediated
through TRAF2 [227]. This observation has two important implications. First, BIRC2 and BCL2
are both 17β-AED target genes and thus, indicate the presence of anti-apoptotic genes that
prevent death derived from the intrinsic and extrinsic pathways in T98G cells. Second, p53
dependent apoptosis is not produced in T98G cells by either 17β-AED or 17α-AED. Therefore,
17β-AED and 17α-AED influence the Rb-E2F rheostat; however, other additional cellular
transcriptional controls coordinate and integrate the biological outcome. More studies will need
to be performed to further elucidate the action and effects of the specific cell-directed stress
responses induced by the presence of 17α-AED and 17β-AED

70

Summary
Targeting cancer through main pathways is fraught with difficulties [233]. 17β-AED and
17α-AED are chemically identical stereochemical epimers that differ only in the position of the
hydroxyl at carbon 17 of the cycloperhydrophenanthrene ring structure (Figure 1). This report
demonstrates, for the first time, that naturally occurring, chemically identical adrenal hormone
(17β-AED or 17α-AED) treatments resulted in the induction of significant, specific yet
differential transcriptional responses to stress that, despite the presence of major mutations,
positively affected the core transcriptional regulatory unit in T98G cells as well as the three
critical pathways inherent to Glioblastoma cells (Figure 17). 17α-AED treatment resulted in type
II programmed cell death while 17β-AED treatment resulted in DNA repair and growth control.
Schematic diagram of the primary sequence alteration for components of the
CDKN2A/MDM2/p53 axis, Ras/PI3K axis, and CDKN2A/CDK4/RB signaling pathways in
T98G cells are shown. Light gray with black lettering indicates inhibiting genetic alterations in
the T98G cells. Dark gray with white lettering indicates a functional mutation differing from the
wild-type. Block Crosses indicate the affected biofunction. 17β-AED affects the
CDKN2A/MDM2/p53 axis by up regulating CDKN2D and p53. 17α-AED affects this axis by
downregulating the mutated p53 and CDKN2D thus the activity of 17α-AED does not require
the CDKN2A/MDM2/p53 axis. Both 17β-AED and 17α-AED affect the Ras/PI3K axis by
modulating AKT. 17α-AED phosphorylates elF2α and thus does not require PTEN for this
function. 17β-AED upregulates CDK2 while 17α-AED downregulates CDK2 and general
translation. Thus both hormones regulate the RB/E2F rheostat without the requirement of
CDKN2A.
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Figure 17: T98G Gene Mutations in 3 Critical Glioblastoma Signaling Pathways

These observations demonstrate that 17α-AED affects the 3 main signaling pathways
without the requirement for the mutated genes in these pathways resulting in irreversible cell
death while 17β-AED induces a cell-directed transcriptional program targeting DNA repair and
growth control despite the presence of the mutations in these 3 pathways
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CHAPTER 4: Pressure Ulcers in Patients with Spinal Cord Injury; Microarray and Network
Analysis

Introduction
Chronic non-healing wounds, primarily pressure ulcers, are a major clinical challenge in
the long-term care of patients with spinal cord injury. Clinical evidence demonstrates that
chronic pressure ulcers are a major source of morbidity and mortality, having a significant
impact on spinal cord injury (SCI) patients’ health and health care resource expenditures.
Chronic pressure ulcers may potentially occur in any SCI (spinal cord injury) patient, as a result
of denervation of skin below the lesion level and impaired mobility.
Wound healing is a multifactorial process which has been elucidated by state-of-the-art
wound care research. Regulation of normal wound healing depends largely on the interactions
among multiple cell types, which includes immune cells (neutrophils, monocytes, lymphocytes
and dendritic cells), endothelial cells, keratinocytes and fibroblasts. Those cells undergo marked
changes in gene expression and phenotype, leading to cell proliferation, differentiation and
migration [234-236]. If this response is successful, these processes will be shut down in a
precise sequence in the ensuing days as healing progresses [235].
In SCI patients, a common and frustrating occurrence is the frequency of skin
breakdown, particularly under bony prominences. A further problem with skin breakdown in
persons with SCI is the slow healing rates (sometimes in excess of 1 year) in comparison with
wounds in other
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clinical scenarios. Over the past 30 years, research has been performed to try to uncover
metabolic and physiological differences between the skin above and below the level of the SCI
[237]. In SCI related chronic pressure ulcers, the normal healing process is significantly altered
and delayed, which may result from multiple physiologic deficiencies in denervated skin.
Several studies have shown that molecular events may be the crucial factors resulting in collagen
and extracellular matrix (ECM) depletion, decreased activity and migration of fibroblasts, and
wound-healing delays [237-242]. However, the precise biologic processes involved in prolonged
SCI-related wound healing are still not completely understood.
Microarray technology has been utilized to examine the expression of a large number of
genes in an experimental condition simultaneously [243]. It has been problematic, however, to
ascertain biological meaning from the use of microarray alone. Here we utilize whole genome
microarray and IPA® network analysis to identify genes that are different and biologically
significant between chronic SCI related pressure ulcers and normal skin controls. In order to
further characterize the transcriptional program within the chronic pressure ulcer edges, we
applied targeted network analysis of known stress related genes that are transcriptionally
regulated by androstene hormones to identify core transcriptional regulators associated with
chronic pressure ulcer and the normal skin controls genes. These results provide a new
understanding of the molecular mechanisms that differentiate chronic pressure ulcers from
normal skin during wound healing.
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Materials and Methods
Protection of Human Subjects
The study was approved by the Investigative Review Board Human Subjects
Subcommittee at the Dallas VA Medical Center and was conducted in accordance with its
regulations. To minimize risk of disclosure to others and discrimination or stigmatization,
measures were taken to ensure confidentiality. Each participant was assigned a confidential code
number to be used by staff when collecting and reporting information. Research staff used coded
forms and confidential code numbers for study participants when collecting and processing test
data. Laboratory samples and results were identified only by confidential code numbers. At no
time did the project release medical or laboratory information that could in any way be linked to
a particular study participant. All data used in this transcript for publication of the findings from
the study were presented in aggregates and without the identities of individual participants.

Recruitment and consent procedures
Six males, aged 20 -70, with paraplegia or tetraplegia hospitalized with chronic pressure
ulcers in a VA SCI center were selected for this research. All patients were receiving at least
daily dressing changes according to their inpatient wound care orders. Explanation was given to
patients who participated in the study and any questions or concerns they might have during the
study were addressed as well. A formal written consent form was given to them to read. All
subjects signed the IRB-approved consent form prior to any interventions taking place. Time was
provided for review so that the client could share his intention to participate with significant
others or family members prior to enrollment.
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Specimens
Two or more skin specimens, about 100 mg each, were excised using a scalpel from each
of six patients. One or more samples were taken directly from the edge of the wound and another
from normal skin above the neurologic level of injury (suprascapular region). All samples were
removed immediately upon excision. Six edge specimens were obtained in patients who had
pressure ulcers which lacked viable granulation tissue, i.e. had a flat, smooth appearance. All
specimens were put in 5ml of RNA later (Ambion) solution and kept in refrigerator before
submission for RNA extraction. Both normal and wound tissues were de-identified prior to
transporting to the lab for further analysis.

Total RNA Extraction from Skin Tissues
Total RNA was isolated from skin specimens using the Lipid Tissue mini kit (Qiagen)
according to manufacturer’s instructions. Briefly, 100mg tissue was homogenized in 1ml
QIAzol Lysis Reagent. After addition of 200μl chloroform and shaking by hand, the
homogenate is separated into aqueous and organic phases by centrifugation. The upper, aqueous
phase is transferred to another tube, and an equal volume of ethanol is added to provide
appropriate binding conditions. The sample was then applied to the RNeasy spin column, where
the total RNA bound to the membrane and phenol and other contaminants were efficiently
washed away. High-quality RNA was then eluted in 100μl RNase-free water. The RNA
concentration was measured by Spectrophotometer (Nano Drop) and RNA quality was checked
by Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA).
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Microarray analysis using Illumina Human-6 BeadChip arrays
a. cRNA amplification and probe labeling: cRNA was amplified and labeled with biotin
for each sample using MessageAmp II-biotin enhanced kit according to manufacturer’s manual
(Applied Biosystems). Briefly, 200ng total RNA was used for the double strand DNA synthesis
with T7-oligo (dT) primer and followed by in vitro transcription (IVT) reaction to amplify cRNA
and incorporate biotin into the synthesized cRNA probe. The cRNA probe was then purified and
quantified by Spectrophotometer. Three labeling replicates were done for each sample.
b. Illumina Human-6 BeadChip hybridization: Biotinylated cRNA probe was hybridized
to the Illumina Human-6 BeadChip Arrays (Illumina, Inc., San Diego, CA), 1,500ng labeled
cRNA was used for hybridization for each array. The hybridization, washing and scanning were
performed according to the manufacturer’s manual instruction. A total of 36 arrays were used
for 12 samples (each sample has 3 replicates). Network analysis was performed on these whole
genome microarrays and the microarray expression data for the 16 genes identified in the most
significant network are represented in Table 5. Additional information on the genes associated
with UBC and that are unique to normal skin edges in network 1 can be found in Appendix 4A.
Additional information on the genes associated with UBC that are unique to chronic pressure
ulcers in network 1 can be found in Appendix 4B. Information on UBC-associated genes that are
shared by normal skin and chronic pressure ulcer can be found in Appendix 4C.
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Table 5: Whole Genome Microarray Network Analysis: Ubiquitin C-centered Networks

Normal skin and chronic pressure ulcer raw data represent the average fluorescence signal intensity measured in fluorescence units [244].
Positive fold change is an increase in signal intensity from the skin control to the chronic pressure ulcer and is calculated as the chronic pressure
ulcer fluorescent units divided by the skin control fluorescent units. Negative fold change is a decrease in signal intensity from the skin control to
the chronic pressure ulcer.
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Microarray data analysis
The microarray data were extracted using BeadStudio v3.1 software provided by the
manufacturer. The data were background subtracted and normalized using Cubic Spline
algorithms. Statistical analysis was performed by comparing the samples between each group
using the Student’s t test with the Bonferroni Correction. All samples and replicates within each
category were pooled as a group.

Network Analysis
Network Core Analysis
An Ingenuity IPA® core analysis was performed where the identified target genes were
overlaid onto a global molecular network developed from information contained in the IPA
database. The Ingenuity Knowledge Base Includes: Data Sources scanned included Ingenuity
expert findings®, mi records, TaRbase, TargetScan Human, BIND, BIOGRID, Cognia, DIP,
INTACT, Interactome studies, MINT, MIPS, ClinicalTrials.gov, GeneOntology, GVK
Biosciences, Kyoto Encyclopedia of Genes, miRBase and the Obesity Gene Map.

Network Statistics (Score)
The network score is a numerical value used to estimate how well the network eligible
genes match the Ingenuity Knowledge Base genes. The score takes into account the total number
of network eligible molecules, network size, and the total number of possible associated
molecules in the Ingenuity Knowledge Base. The Network Score is based on the hypergeometric
distribution and is calculated with the right-tailed Fisher's Exact Test. For example, a network of
35 molecules has a Fisher Exact Test result of 1x10-8. The network’s Score = -log (Fisher's Exact
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test result) = 8. This is interpreted as there is a 1 in a 100 million chance of obtaining the 35
molecule network containing network eligible molecules randomly that could be in networks
generated from the Ingenuity Knowledge Base.
Core regulator Analysis of Chronic Wounds
To evaluate and identify associations with core transcriptional regulators involved in
stress we analyzed each gene that was different between the UBC centered Network 1 of the
Normal Skin Control and the UBC centered Network1 of the Chronic Pressure Ulcer by running
individual IPA®core analyses of each gene, its known binding partners identified in Ingenuity®
and known ER (endoplasmic reticulum) stress sensors (ERN1, PERK, and ATF6)[245], and
known genes associated with programmed cell death (PI3KC3, beclin-1, SQSTM1)[246].
Δ5-androstene-3β, 17α-diol (17α-AED) has been shown to produce definitive type II
programmed cell death in T98G cells [157]. The mechanism whereby 17α-AED induces
oncophagy in T98G cells has previously been identified and described [195][196]. Δ5androstene-3β, 17β-diol (17β-AED) is the epimer of 17α-AED. These naturally produced adrenal
hormones are chemically identical and differ only in the stereoisomeric position of the hydroxyl
group located at carbon 17 of the steroid ring structure. 17β-AED, in opposition to 17α-AED,
does not produce cell death in T98G Glioblastoma cells [196]. 17β-AED, in fact, promotes
significant biological effects including the enhancement of the immune system [81][197] even in
the presence of glucocorticoids [112][109] and provides protection against lethal radiation [198].
We have prior shown that these two androstene hormones regulate 26 genes related to
regulation of ER stress which include or are associated with core transcriptional regulators. 17α
and 17β-AED regulate these genes in an opposing manner that is at least 1 order of magnitude
different. Thus these 26 genes are intricately involved in the modulation of the stress response
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and these 26 genes (Table 3) represent a set of regulatory genes that are involved in the cell
directed decision to upregulate immunity, repair genomic material or self destruct through
programmed cell death mechanisms. Both 17β-AED and 17α-AED regulated a specific cell
directed response to stress. Because Chronic wounds represent a stressed cellular environment it
was imperative to evaluate the transcriptional regulation of the 26 genes and identify the
association of these core regulators with genes that were identified as significant from the
network analysis of the whole genome array within the chronic wound edges.

Results and Discussion
Chronic pressure ulcers represent a stressful environment for the cells residing there.
Environmental changes cause cells to alter collections of expressed proteins in order to maintain
homeostasis. Protein expression patterns are known to be modified in stressed conditions through
transcriptional, translational and post-translation mechanisms [247]. Cellular functions including
cell survival, death, proliferation, differentiation are realized through the transcription,
translation and degradation of large multi-protein complexes. The modular components must
either be sustained or degraded based on cellular control. It is now understood that the cellular
timescale does not always apply to the abrupt appearance or disappearance of the rate limiting
components of transcription and translation molecular "machinery". The ubiquitin proteosomal
system, by regulating activating and deactivating regulators through post-translational
degradation of cellular proteins, centrally orchestrates cellular functions [248].
Ubiquitin is a highly conserved protein consisting of 76 amino acid that targets substrate
proteins for degradation through the 26S proteosome [11]. The ubiquitin proteosomal system has
emerged as the principal system of protein fate inside cells [249]. Ubiquitination can result in
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degradation of native correctly folded proteins for the purpose cellular process control including
transcription, signal transduction and development [250]. However, ubiquitination can also
degrade unfolded or misfolded proteins in the endoplasmic reticulum (ER) through a process
termed Endoplasmic Reticulum Associated Degradation (ERAD). Protein folding is inherently
error prone. In addition, many variable stress stimuli such as hypoxia, bacterial infection,
repetitive ischemia/reperfusion and altered cellular and systemic stress responses bear on chronic
pressure ulcers and may compromise the rate or efficiency of protein folding [251][252].
Proteins are assembled in the endoplasmic reticulum and secreted proteins are subjected
to ER quality control [253]. When proteins attain their native conformations they may be
directed to their final destination. When proteins do not achieve their native conformations they
are subjected to further processing to achieve proper folding. If the proteins do not achieve their
native conformation after ER quality control processing then they are subjected to ERAD [254].
ERAD is a complex process and proteosomal degradation can occur with mechanisms outside
the ubiquitin pathway, however ubiquitination is the major mechanism associated with
degradation of proteins through the proteosome [252].
It is well established that attachment of ubiquitin occurs through a cascade of three
enzymes; E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3
(Ubiquitin E3 Ligase) [252][255]. Activation of ubiquitin by E1 initiates the process. Then the
activated ubiquitin is transferred to the E2 and finally the E2 conjugate associates with the E3
ligase and the E2/E3 complex transfers the ubiquitin to a lysine in the protein target [256]. The
specific combination of E2 and E3 enzymes determines the chain linkage type [257]. Ubiquitin is
the common denominator for proteosomal, lysosomal and autophagosomal degradation [257].
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The IPA® core analysis was performed on the whole genome microarray as described.
The normal skin microarray and the chronic wound microarray each produced 25 individual, 35
gene networks. Investigation of the core analysis showed that the major network (most
significant) for both the normal skin control (Score: 36) and the chronic pressure ulcer (Score:
36) was ubiquitin C centered. Ubiquitin C is an E2 enzyme that has been shown to be a part of
evolutionarily conserved E2/E3 complexes [250]. Normal skin and chronic wound networks
were 77% similar with 27 identical genes and 8 different genes associated with UBC (Figure 18).
CERCAM (cerebral endothelial cell adhesion molecule), LMF2 (Lipase maturation factor
2), SLC22A17 (solute carrier family 22 member 17), UBAP1 (Ubiquitin associated protein1),
RNF145 (ring finger protein 145), and C8orf76 (chromosome 8 open reading frame 76) were all
upregulated in the chronic pressure ulcer as compared to the normal skin control. CLIP3 (CAPGLY domain containing linker protein 1) and RNF24 (ring finger 24) were the only genes that
were not transcriptionally affected, however CLIP3 and RNF24 became associated with
Ubiquitin C in network 1 of the chronic pressure ulcer (Table 5) indicating a functional shift
involving the association between UBC and these genes. In general, it can be stated that these
eight genes are associated with Ubiquitin C (UBC) in the chronic wound and may represent
treatment targets or treatment indicators in these currently difficult-healing chronic pressure
ulcers.
Six of the eight different genes in the normal skin control (Figure 18) possessed
transcriptional differences (Table 6.). Additional gene information can be found in Appendix 2
and 3. Of the eight genes, only NCCRP-1 (non-specific cytotoxic cell receptor protein 1
(zebrafish)) was upregulated in the chronic pressure ulcer. KPRP (keratinocyte proline rich
protein) and RILPL1 (Rab interacting lysosomal protein-like 1) did not have significant

83

expression changes. DEF8 (differentially expressed in FDCP 8 homologue (mouse), THUMPD1
(THUMP domain containing 1), MMGT1 (membrane magnesium transporter 1), BEX4 (Brain
expressed X-linked 4), and SECISBP2L (SECIS binding protein-2 like) were all slightly
downregulated. These findings imply a loss of normal skin functionality related to these UBCassociated genes.

A) Skin Control

B) Chronic Pressure Ulcer

Figure 18. Network schematic of genes that are associated with UBC in the A) the normal
skin network #1 or B) the chronic pressure ulcer network #1. These genes are present in both
the normal skin and the chronic pressure ulcer. The 8 genes associated with UBC in the chronic
pressure ulcer are not associated with UBC in the normal skin and the 8 genes associated with
UBC in the normal skin are not associated with UBC in the chronic pressure ulcer.

84

Cerebral Endothelial Cell adhesion Molecule (CERCAM) is a gene that is significantly
associated with UBC only in the chronic pressure ulcers. This gene is widely transcribed in the
nervous and secretory tissues including salivary gland, pancreas, liver and placenta [258].
CERCAM has been shown to be a glycosylated binding partner of Fbox06 [259]. CERCAM is
related to CoLGALT1 and CoLGALT2 but does not possess the ability to glycosylate collagen
and it possesses an ER localization signal and localizes to the ER like COLGALT1 and
COLGALT2 [258]. CERCAM was first described as a cerebral adhesion molecule and bound to
CDllb/Cd18 and was suggested to be involved in leukocyte trafficking which is associated with
inflammatory processes [260]. It is unknown whether this protein glycosylates different proteins
other than collagen [261].
CERCAM was mapped to a genetic locus in the wrinkle free mouse (wrfr), an autosomal
recessive mouse mutation that results in extremely tight, thick skin [262]. Interestingly, the
wrinkle-free mice die shortly after birth and the phenotype is similar to restrictive dermopathy
[262]. Taken together, these observations suggest that CERCAM is associated with a defective
skin barrier while facilitating leukocyte trafficking and that these processes are associated with
Fbox06 related ubiquitination processes in the chronic pressure ulcers of SCI patients.
CERCAM was found to be upregulated (2.89 Fold, p < 0.001) in the chronic pressure
ulcers (Table 5.). Targeted core and stress regulator network analysis demonstrated that
CERCAM associated with p53 and CDK2 through UBC and SQSTM1 suggesting that these core
regulators may influence the expression of CERCAM and the SQSTM1-p53 association may
influence the UBC-CERCAM interaction and influence the stress response and/or survival
decision made by the cells.
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LMF2 (lipase maturation factor 2) is another gene that, similarly to CERCAM is a
glycated FboxO6 binding partner [259]. LMF2 is slightly yet significantly upregulated (1.23
Fold, p< 0.05) in the chronic wound. This further supports a role for FboxO6 in ubiquitin
regulation of proteins in the chronic pressure ulcer. FboxO6 is associated with ubiquitination and
degradation of glycated proteins in a process termed GERAD (Glycated Endoplasmic Reticulum
Associated Degradation) [263]. The significant association of FboxO6O associated genes with
UBC may point to the importance of ubiquitination of glycated proteins in the CPU.
LMF2 was originally identified as a potential gene involved in lipid metabolism [264].
LMF2 is 42% homologous to LMF1, however, LMF2 cannot complement or rescue LMF1
deficient cells suggesting a different role for LMF2 [264]. While a physiologically relevant and
non-redundant role was suggested for LMF2, there is no further information about this gene
available.
Little is known about the function of RNF145 although it was found to structurally
cluster closest with RNF139 (TRC8) with both RNF proteins containing multiple membrane
domains [265]. RNF145 is a putative human transmembrane RNF protein [266][265]. RNF
domains are composed of 40-80 amino acids and contain eight conserved cysteine and histidine
residues that chelate two zinc ions to form a cross-brace structure which allows correct folding
and function of the RING [266][265]. RNA domains have 3 classifications based on the structure
of the finger: C3H4 (RING-HC), C3H2C3 (RING-H2) or C4HC3 (RING-CH or RINGv). RNF
145 possesses the C3HC4 (RING-HC) RNF domain. The RNF domain is a scaffold for binding
to E2 enzymes closely with substrate proteins which allows for efficient transfer of ubiquitin to
substrate proteins [267].
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Ring Finger 145 (RNF145) was found to be significantly upregulated (1.82 Fold, p <
0.001) in the chronic pressure ulcers (Table 5.). Humans possess an expanded repertoire of E3
Ligases that are available to accomplish ERAD [268]. RNF 139 was found to be an E3 Ligase
that is involved in ERAD of normal and abnormal proteins and intriguingly, this multi-function
ligase is targeted by a human CMV virus protein which results in ubiquitination and destruction
of MHC I [268]. In a similar fashion, the high structural similarity of RNF145 to RNF139
suggests that this E3 ligase is involved in ERAD within the CPU. RNF 145 function and
interactions have not yet been characterized yet RNF 145 upregulation along with UBC
association in the chronic pressure ulcer demonstrate that RNF145 may play a role in
proteosomal protein degradation. Individual analysis of RNF145 in relation to targeted core and
stress regulators associated p53 with RNF145 through UBC. These observations imply that
RNF145 may be functionally associated with p53 directed processes within the chronic pressure
ulcer.
UBAP1 is another transcriptionally regulated gene (1.53 fold, p<0.001), UBAP1
(ubiquitin associated protein 1) is a component of endosomal sorting complex 1 (ESCRT1) and
is associated with Vps28, Vps37A and TSG101 [269][270]. The ESCRT system has been well
described [271-274]. ESCRTS are multi-protein complexes that function in the biogenesis of
multi-vesicular bodies [272]. UBAP1 forms a heterotimeric protein complex that contains
multiple ubiquitin binding domains with Vps28, Vps37A and TSG101 allowing ESCRT1 to
readily acquire ubiquinated membrane proteins cargos [269].
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Figure 19. UBAP1 Related Core Master Transcriptional Regulator Network
Genes above the large box represent members of the UBAP1 containing ESCRT1 system.
ESCRT1 consists of Vps28, Vps37A, TSG101, and UBAP1. Known linkages of ESCRT1 with
the main transcriptional regulators are through GCR (glucocorticoid receptor) and ERK1/2.
Genes/histones to the right of the box represent known links to the transcriptional regulators.
p300/CBP provides a linkage that unites all the transcriptional regulators within the large box
containing the most significantly associated transcriptional regulators. The dotted line indicates
the EGFR regulation by ESCRT1 through UBAP1.
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Membrane bound proteins are sorted through multi-vesicular bodies upon binding to ubiquitin.
Ubiquitinated proteins are then recognized through a series of ESCRTs which contain multiple
ubiquitin binding domains coordinate and complete the formation of intraluminal vesicles.
A salient feature of UBAP1 in this system is the linkage between UBAP1 and
EGFR1degradation. UBAP1 was shown to be necessary and sufficient to degrade EGFR from
the cell membrane via ubiquitin binding and lysosomal degradation [272][272]. EGFR signal
transduction is well documented to boost immune and tissue repair abilities of damaged tissue
[275-277]. Thus, loss of EGFR and its signal transduction abilities greatly alters the ability of the
cells in the wound edge to respond with programs of tissue repair or immunity. EGFR
transcription was also affected. EGFR was downregulated (-1.71 Fold, p<0.001)) in the CPU as
compared to the normal skin control. Individual analysis of UBAP1 in relation to targeted core
and stress regulators demonstrated a relationship with a set of core transcriptional regulators
(Figure 4). UBAP-1 demonstrates how ubiquitin integrates proteosomal and lysosomal
degradation; signal transduction and transcriptional regulation to obtain a biological response.
The upregulation of UBAP-1, association of UBAP-1 with UBC in the chronic pressure ulcers
with concomitant downregulation of EGFR transcription indicates transcriptional and possibly
ubiquitin/proteosomal downregulation of EGFR in the chronic pressure ulcer.
SLC22A17 is also a gene shown to have significant transcriptional regulation (in the
chronic wound analysis. SLC22A17 (Solute Carrier Family 22, Member 17) is a 25kDa protein
that belongs to the lipocalin superfamily. SLC22A17 is structured to uptake small lipophilic
molecules including hormones, retinoids, arachadonic acid and fatty acids. SLC22A17 will
transport its lipocalin 2 (LCN2) ligand either alone or bound to iron [278]. Transport of
Lipocalin bound with iron leads to cell survival whereas unbound lipocalin leads to apoptosis
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[279][280]. It was also shown that LCN2 had anti-microbial properties by sequestering iron
away from invading bacteria [279].
Previously it was demonstrated that BCR-ABL would influence the expression of LCN2
and SLC22A17. BCR-ABL is a fusion protein that possesses constitutively active ABL tyrosine
kinase activity promoting proliferation and survival [281]. BCR-ABL signaling caused a
dysregulation of LCN2 and SLC22A17 where LCN2 was upregulated in BCR-ABL containing
cells while SLC22A17 was not leading to an apoptotic effect on surrounding cells but allowing
survival of transformed BCR-ABL cells. Overexpression of SLC22A17 was shown to induce
apoptosis in transformed cell lines indicating that downregulation of SLC22A17 is critical for
survival in the presence of LCN2 [282]. Together, these observations indicate that the presence
of LCN2 with
In contrast to cells containing the BCR-ABL oncogenes, LCN2 in the chronic wounds
was upregulated (2.31 Fold, p<0.001)) in conjunction with a slight upregulation in SLC22A17
(1.22 Fold, P<0.05) (Table 5.). LCN2 was prior observed in wound fluid demonstrating that
regulation of SLC22A17 is critical to cell survival [283]. While the cells and cellular
mechanisms involved are unclear, upregulation of SLC22A17 has been shown to predispose
cells with the SLC22A17 receptor to apoptosis through LCN2 while cells that downregulate
SLC22A17 are protected from LCN2- induced cell death [284]. Targeted core and stress
regulator network analysis demonstrated that SLC22A17 is associated only with UBC indicating
an indirect relationship between SLC22A17, UBC and the core stress regulators and
demonstrating the importance of ubiquitin in the regulation of this receptor.
LCN2 has been directly associated with non-healing chronic pressure ulcers [283].
Wound fluid from non-healing chronic venous pressure ulcers were shown to contain persistent
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LCN2 levels with concomitant Toll-Like Receptor 2 and 4 activities [283]. Healing wounds
demonstrated decreased Toll like receptor activity and LCN2 levels [283]. Since Toll-Like
receptors are associated with innate immune responses then this implies that an abnormal innate
immune response is related to the multifactorial environment present within the chronic wounds.
Since 17β-AED and 17β-AET have been shown to possess innate immunity functionality
associated with protection and survival in cells undergoing stress then it follows that these
hormones may possess the ability to stimulate an effective innate immune response within the
chronic wound [103,351].
RNF24 is an E3- ubiquitin ligase that has been associated with Huntington's disease.
RNF24 has a C3-H2-C3 (RING-H2) RNF domain [265], is localized to the Golgi apparatus and
was shown to interact with ankyrin-repeats domain(ARD) of TRPC (transient receptor potential
channel) channels 1,3,4,5,6 and 7 [285]. RNF24 with its RING-H2 RNF domain was shown to
not affect calcium channel-induced expression of RNF24, and did not affect the maturation
process of TRPC6 and yet significantly reduced the cell surface expression of TRPC6 suggesting
that RNF24 interacts with TRPC channels in the Golgi and affected intracellular trafficking
[285]. Therefore, it is possible that UBC can affect cell secretion, contraction, growth,
differentiation and apoptosis through the regulation of RNF24.
Individual analysis of individual analysis of RNF24 in relation to targeted core and stress
regulators associated p53, CTSD, GYS1, and PI3KC3 with RNF24 through UBC. These genes
are well known for directing cell death programs in many different cell types
[220][286][287][288][289][245]. Transcription of RNF24 is not significantly different between
the CPUs and normal skin yet this E3 ubiquitin ligase becomes associated with UBC in the
chronic wound suggesting a function for the UBC-RNF24 association in the chronic wounds.
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CLIP3 (CAP-GLY domain containing linker protein 3) is a gene that codes for the CLIP170-related protein of 59 kDa and this protein is different than other CLIP proteins [290]. CLIP3
is a gene related to apoptotic function and is not transcriptionally affected in the chronic pressure
ulcers (Table 5). Recently, CLIP3 in conjunction with cylindromatosis turban tumor syndrome
(CYLD) protein was shown to regulate RIP1 ubiquitination and promote caspase-8 activation
and apoptosis in the context of TNFα signaling [291]. Upregulation of CLIP3 expression
enhanced while CLIP3 silencing inhibited the apoptotic activity of CYLD [291]. It was proposed
that CLIP3 in conjunction with CYLD accomplishes de-ubiquitination of RIP1 and subsequent
apoptosis [291].
CYLD was, however, downregulated (-2.14 Fold, p<0.001) in the chronic pressure ulcers
while the CLIP3 expression change was insignificant. CLIP (cytoplasmic linker protein) proteins
are associated with intracellular organization and movement through regulation of microtubules
[292]. CLIP-3 differs from other CLIP proteins in that it does not bind to microtubules, is
localized to the Golgi, contains a Golgi localization domain that is known to be necessary for
addressing cytosolic proteins to the Golgi and is part of the trans-Golgi network [293].
Additionally it was noted that CLIP3 was associated with lipid rafts in HeLa cells and regulates
AKT cellular compartmentalization by associating with phospho-AKT [290][294].
Overexpression of CLIP3 was shown to interfere with microtubules and thus CLIP-3 is thought
to contain some anti-CLIP function thus perturbing intracellular organization and movement
[290]. Thus, CLIP3 in the presence of downregulated CYLD may indirectly perturb the
intracellular organization and movement of cells and thus the immune response present in the
chronic pressure ulcer edges.

92

It should be noted that RIP1-mediated, pro-apoptotic signaling may be dependent
on cell type and context [291]. Individual analysis of CLIP3 in relation to targeted core and
stress regulators demonstrated that CLIP3 is mainly associated with RIP1 and TNFRSF1;
however, UBC is associated with p53, CDK2 and cJUN. Thus these regulators may indirectly
influence the activity of CLIP3 and may affect the cell death decisions of the cell(s).
NCCRP-1 (Non-specific cytotoxic cell receptor protein-1) was originally cloned from
catfish, zebrafish, tilapia, gilthead bream and carp and was predicted to be either a Type II or
Type III membrane receptor [295- 300]. Non-specific cytotoxic cells are the equivalent to natural
killer cells in the teleost fishes [301]. NCCRP-1, however, was absent on the surface of cells and
subsequently was found to contain homology with the F-box only proteins [302]. NCCRP-1
activity was suggested to be responsible for immune functions of nonspecific cytotoxic cells in
fish [295]. F-box functions include protein-protein binding of protein substrates in E3 ubiquitin
multi-subunit ligases for subsequent ubiquitination by the ubiquitin proteolytic system [303].
The microarray analysis indicated that NCCRP-1 was present in the most significant
UBC network of the normal skin control; however, NCCRP-1 was upregulated (2.10 fold,
p<.001) while the UBC association was lost in the chronic pressure ulcers, in chronic pressure
ulcers (Table 5.). NCCRP-1 has been shown to have 5 paralogues in humans: FBX02, FBX06,
FBXO17, FBX027 and FBX044 which function as part of E3 ubiquitin ligase complexes [304].
Sequence alignments of NCCRP-1 and structural interpretations suggested NCCRP-1 to be part
of the lectin Type subfamily of Fbox proteins and it was suggested to be renamed as FBXO5O
[302]. Fbox proteins have been shown to be present and impart functionality to E3 ubiquitin
multi-subunit ligases [305][306][307]. Thus, upregulation of FboxO5O protein (NCCRP-1) and
upregulation of FboxO6O-associated proteins and the lack of association of NCCRP-1 with UBC
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in the chronic pressure ulcers suggest that the NCCRP-1-UBC association has lost significance
in the chronic pressure ulcer. Upregulation of NCCRP-1 may indicate an individual functional
role in the dysfunction of the chronic pressure ulcer.
Individual analysis of NCCRP-1 in relation to targeted core and stress regulators
indicated that the core regulatory genes associated with NCCRP-1 are p53, CDK2, cJUN and
ESR1 with indirect associations between ELAVL1 (discussed below) and UBC (Figure 3). These
core transcriptional regulators may underlie the upregulation of NCCRP-1. Furthermore ESR1 is
known to influence immune functions and its presence may indicate involvement with cJUN,
p53 and ELAVL1 in the transcriptional regulation of NCCRP-1 [308]. The exact role of
upregulated NCCRP-1 with the loss of UBC-association in the chronic pressure ulcer is unclear.
NCCRP-1 and MMGT1 are genes present in the individual targeted core and stress
regulator networks that contain UBC with a connecting network edge to ELAVL1 (ELAV
(embryonic lethal, abnormal vision, Drosophila)-like 1(Hu antigen R))`. ELAVL1 is an RNAbinding Protein that can promote RNA stability and influence transcription [309][310]. In stresstreated and untreated cells ELAVL1 was shown to elevate some key target genes including p53
which is part of a cellular transcriptional core regulatory unit [220]. Additionally ELAVL1 has
been shown to stabilize many target mRNA's including those that encode stress-response and
proliferative proteins including CDKN1A, Cyclins, iNOS, HIF1-α, VEGF, SIRT1, TNFα, BCL2, and DUSP-1 [311-317]. Heat shock studies showed that transcriptional levels of HuR mRNA
did not change in heat shock but rather that HuR protein stability was reduced [318]. Ubiquitin
has been associated with ELAVL1 through the following observations: ELAVL1 was
ubiquitinated in vitro and CHK2 kinase protected against ELAVL1 loss while proteosome
inhibition led to an increase in ELAVL1 abundance [318].
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In opposition to heat shock, ELAVL1 is downregulated in the chronic pressure ulcers
(-2.4 Fold, p <0.001). This observation demonstrates specificity of ELAVL1 to heat shock
responses and suggests that the wound environment is not undergoing a heat shock response.
Targeted network analysis demonstrated a UBC association with ELAVL1 to the normal skin
control proteins. ELAVL1 was not associated with any of the targeted core and stress regulator
analyses of the 8 UBC associated proteins unique to chronic pressure ulcers and the
transcriptional downregulation of ELAVL1 in chronic pressure ulcers may indicate its
background role of this protein in normal skin.
MMGT1 is a gene that encodes a protein that is located in the Golgi complex and postGolgi vesicles. MMGT1 is known to transport strontium, iron, cobalt and copper [319].
Originally MMGT1 was thought to contribute to the regulation of magnesium- dependent
enzymes that are involved in protein assembly and glycosylation [320]. Later, an integrated
mapping strategy identified MMGT1 as part of the mEMC (mammalian Endoplasmic Reticulum
Membrane Complex) which was one of six ERAD related functional modules that perform
substrate recognition, dislocation, extraction, ubiquitination and proteosomal degradation [321].
The function of the mEMC is currently unknown although MMGT1 is present in the normal skin
suggesting that the MMGT1 association with UBC/ELAVL1 is present in the normal skin and
may be important for the functioning of normal ion transport and ERAD in the skin [321].
MMGT was slightly downregulated in the CPU (-1.16, p<0.001). ). Individual analysis of
MMGT1 in relation to targeted core and stress regulators demonstrated MMGT1-ELAVL1 and
MMGT1-UBC associations. However, MMGT1 is not associated with UBC in the CPU.
Together these observations suggest transcriptional rather than UBC regulation of these genes in
the chronic wound.
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BEX4 is localized to the x-chromosome and is located between BEX1 and BEX2 and is
notably expressed uniformly and at high levels and is found in the nucleus and cytoplasm
(passive diffusion) in the heart, skeletal muscle, liver and kidney [322]. BEX4 expression in
primary cell lines correlated with promoter methylation. It was shown that overexpression of
BEX4 induced apoptosis in cancer cell lines [323] and that loss of BEX4 was associated with
deregulation of c-Myc activity, cyclin D1 levels resulting in cellular transformation [323]. Thus,
these data implicated BEX4 as a tumor regulatory protein [323]. Individual analysis of BEX4 in
relation to targeted core and stress regulators demonstrated an association with UBC that was
indirectly affected by BRCA-1, CDKN1A, p53 and CDK2. TP53 is the common gene between
these networks. BEX4 is downregulated (-1.39, p<0.001) in the chronic pressure as compared to
the skin control (Table 5.). Together with the loss of association with UBC this gene also
demonstrates transcriptional regulation with concomitant loss of UBC association. Both the
presence and role of BEX4 and the BEX4-ELAVL1-UBC associations in both the normal skin
control and the chronic pressure ulcers of SCI patients are unknown.
KPRP is a newly identified epidermal protein associated with the upper granular
components of the cornified layer of the skin [324]. KPRP was previously identified in a
specialized high throughput screen of the transcriptome of importance for epidermal barrier
function [325]. Independently, KPRP was suggested to be a marker of stratified
epithelia(granular layer) with a potential role in keratinocytic development [324]. This gene was
expressed in both the skin control and chronic pressure ulcers in SCI patients (Table 5.).
Individual analysis of KPRP in relation to targeted core and stress regulators demonstrated a
direct association with CDK2 and indirect associations with p53, cJUN, EGFR, GSK3B, PI3K,
HoxB1 through Histone 3 (Figure 2). A protein-protein association of CDK2 and KPRP was
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identified in embryonic stem cells [326] and may indicate the involvement of stem cells in the
skin. Additionally, it was noted that the expression of HoxB1 is associated with regulation of the
retinoblastoma tumor suppressor [227] while association with Histone 3 implies epigenetic
regulation. These observations demonstrate that KPRP is intricately associated both directly and
indirectly with these key core regulators. It is unknown whether loss of the UBC association in
the chronic pressure ulcer adversely affects the UBC-related effects on KPRP present in the
normal skin.
THUMPD1 was identified through a genetic linkage and T-cell gene expression
study [327]. THUMPD1 was mapped to a peak linkage within Tsi1 (T-cell secretion of
interleukin) and this locus is associated with high expression levels of IL-4 [327]. Thus,
THUMPD1 (Thump domain containing 1) is an immunity related gene that is transcriptionally
downregulated between the normal skin control and the Chronic Pressure Ulcers (Table 5.). This
gene was proposed to be a key regulator of in-vitro Th2 differentiation at the Tsi1 locus and was
found to be over expressed in BALB/c mice as compared with B6 mice [327]. Interestingly,
RNA message stability was proposed as a possible mechanism for the differential expression of
THUMPD1 between the two mice strains and it was noted that message stability could be due to
a deletion of an AU-rich element in the BALB/c mouse which would predispose this message for
quick degradation if it were present. Targeted core and stress regulator network analysis
demonstrated that THUMPD1 is associated only with UBC thus an association with the core
transcriptional regulators has not yet been shown. THUMPD1 is markedly downregulated (-4.93,
p<0.01) in the chronic pressure as compared to the skin control (Table 5.). Together with the loss
of association with UBC this gene also demonstrates transcriptional regulation. The role of the
UBC-THUMPD1 association with immune responses in the CPUs is unknown.
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DEF8 (Differentially Expressed in FDCP 8 Homolog) is also, associated with
immune functions in the normal skin control. DEF8 was identified as one of 32 genes
overexpressed in the Cd14+ unstimulated peripheral blood monocytic control cells from hyperimmunoglobulin (IgE) syndrome (HIES) patient [328]. HIES is characterized by staphylococcal
infection, eczema and high levels of IgE [329][330]. HIES is a multi-syndrome disease and it
was suggested that the molecule (s) responsible for the disease would need to affect various
biological functions rather than only Th1 or Th2 T-cell responses [328]. Targeted core and stress
regulator network analysis demonstrated that DEF8 is associated only with UBC demonstrating
that an association between DEF8 and the core transcriptional regulators has not yet been shown.
This suggests regulation by UBC rather than stress regulators in the normal skin. DEF8 is
downregulated (-1.16, p<0.001) in the chronic pressure as compared to the skin control (Table
5.). Together with the loss of association with UBC this gene also demonstrates transcriptional
regulation with concomitant loss of UBC association. The precise role of the UBC-THUMPD1
association with immune responses in the CPUs is unknown.
Nitrosylation is a form of oxidative stress. Transnitrosylation is known to affect 3000
proteins and is well associated with nitric oxide synthases which can result in apoptotic
programmed cell death [331] [332]. RILPL1 (Rab interacting lysosomal protein-like 1 is
associated with cell survival and cell death and it is known to compete with SIAH (a RING
finger E3 Ligase) in binding nitrosylated GAPDH generated from diverse cellular stimuli [333].
S-Nitrosylation was shown to eliminate catalytic activity of GAPDH cause binding of GAPDH
to Siah (a RING finger E3 ligase)[334]. Binding of GAPDH to SIAH uncovers a nuclear
localization signal located in Siah and causes nuclear translocation of the GAPDH/Siah complex
to the nucleus where it binds to p300/CBP and affects acetylation of master transcriptional
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regulators including p53 [334]. RILPL1 is a protein that is also S-nitrosylated and was found to
competitively bind to Siah and prevent the nuclear translocation of GAPDH. RILPL1 is not
transcriptionally regulated in the CPUs (Table 5.) while GAPDH is upregulated (1.93, p<0.001)
fold in the CPU. This may indicate an increased sensitivity of the cell toward apoptosis from
oxidative stress in the CPU wound edges.
Individual analysis of RILPL1 in relation to targeted core and stress regulators
demonstrate an association of RILPL1 with SQSTM1 (p62) showing the significance of the
RILPL1 and SQSTM1 association. This association was discovered in the delineation of the
response of the toll like receptors to viral infections [335]. Individual stress network analysis
demonstrated that RILPL1 is affected indirectly by both NFkB and AP-1 through SQSTM1.
RILPL1 is located in the normal skin control and is associated with ubiquitin. This association is
lost in the CPU and may indicate a different biological effect of RILPL1.
SECISBP2L (SECIS binding protein 2-like) is involved in selenocyteine incorporation
into selenoproteins in humans [336]. Selenoproteins have an essential physiological role in
oxidative stress defense [337]. Selenium deficiency, and numerous mutations in selenoproteins
and selenoenzymes have been linked to various disorders of the endocrine, central nervous,
muscular, cardiovascular, and immune systems in man [338] SBP2-like (SECISBP2L) protein is
a homologue of SBP2 [336]. Survey of eukaryotic SECIS binding proteins (SBPs) found that
SBP2 and SECISBP2L are paralogues in vertebrates [336]. SECISBP2L is the sole SBP in some
invertebrates including sea urchins, sea squirts, and an annelid worm in the genus Capitella
[339]. Conservation between SBP2L in vertebrates, invertebrates and mammals suggested role
for SBP2L in the post-transcriptional regulation of selenoprotein expression [339].
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SECISBP2L and SBP2 were found to be different in their ability to incorporate
selenocysteine and SBP2 or SECISBP2L immunoprecipitation experiments showed specific
association of selenoprotein mRNAs (GPX1 and GPX4) with both SBP2 and SECISBP2L [336].
The results showed that mammalian cells have at least two selenoprotein mRNP populations and
suggested a role for SECISBP2L in the post-transcriptional regulation of selenoprotein
expression [336]. SECISBP2L was associated with UBC in the normal skin controls but was
transcriptionally downregulated (-1.39 Fold, p<0.001) in the chronic pressure ulcer tissue (Table
5.). Individual analysis of SECISBP2L in relation to targeted core and stress regulators
demonstrated an indirect association of SECISBP2L with core stress regulators. Together with
the loss of association with UBC this gene also demonstrates transcriptional regulation with
concomitant loss of UBC association. The association with UBC in both the normal skin control
and the chronic pressure ulcers of SCI patients are unknown.

Summary
Chronic pressure ulcers are notoriously hard to heal. One main problem is the fact that
these develop over bony prominences due to pressure, moisture and shear forces [340]. Ulcer
formation over the bony prominence then predisposes the affected individual to microbial
infection and secondary health problems such as osteomyelitis [341]. Skin substitutes have been
evaluated and are sometimes utilized on the legs and feet where they have some success but
information is generally lacking and it is known that these are not very effective where bony
prominences exist. Additionally, evaluation of CPU in SCI patients has indicated that all phases
of wound healing, with the exception of collagen breakdown, are adversely affected in these
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patients with hypoxia and inflammation playing central roles in the detrimental, anti-healing
environment present in the CPUs of these patients [342].
In this study we have utilized microarray and IPA®Network analysis to probe wound
edges in spinal cord injury patients with chronic pressure ulcers and compared these results with
results obtained from normal skin controls in the same patients. Whole genome analysis
combined with IPA®Network analysis yielded one, comparable network between the chronic
pressure ulcers and the normal skin control that was of the highest statistical significance. This
network was UBC centered and differed in 8 genes from normal skin (Table 5).
The central position of UBC is critical because ubiquitin is the central common
denominator for both the chronic pressure ulcer and the normal skin. Ubiquitination is a posttranslational modification that can function in different ways but includes proteosomal,
lysosomal and autophagosomal degradation [257]. Ubiquitination can also affect signal
transduction and activating/deactivating functions associated with genes [305]. Investigation of
the each gene within the normal skin and chronic pressure ulcer networks demonstrated that each
gene was associated with a particular biofunction (Table 6).
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Table 6: Functions of Genes Associated with UBC in Normal Skin Controls and Chronic
Pressure Ulcers of Spinal Cord Injury Patients

The eight genes identified as unique to chronic pressure ulcers represent treatable targets
of chronic pressure ulcers. Stress gene related network analysis was utilized to probe the nature
of the chronic pressure ulcers for the association of transcriptional regulators known to be
directed by androstene hormones. Core transcriptional regulators associated with the androstene
hormone directed stress response can be seen underlying the association with UBAP1 (Figure
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19) which was a gene associated with endosomal trafficking and degradation of membrane
proteins essential to wound healing. This demonstrates the link between ubiquitin-proteosomal
activity and the core regulators transcriptionally affected by androstene hormones.
.
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CHAPTER 5: General Discussion and Overall Conclusion

The study of the cortical adrenal hormones has been intense over the last 70 years. The
discovery that hydrocortisone alleviated symptoms of rheumatoid arthritis was a major
breakthrough and resulted in the belief that adrenal cortical steroids had anti-inflammatory
properties. Subsequently, the discovery and intense study of β androstene hormones (primarily
DHEA, 17α-AED, 17β-AED and 17β-AET) demonstrated that a plethora of debilitating humans
diseases could be positively affected through the administration of these β androstene hormones.
Variable results obtained through different studies have yielded some skepticism about the utility
of these hormones despite large volumes of data supporting the positive effects obtained after
administration of these adrenal hormones.
There have been few major insights into the cellular and molecular mechanism of action
of these androstene hormones in the last 20 years. The overall rationale of these studies was to
further advance the knowledge of the cellular and molecular actions related to these androstene
hormones utilizing traditional biological (reporter assays and microarray) and advanced systems
biology methods (network analysis) with emphasis placed primarily on 17α-AED and 17β-AED.
This represents the first time ever that this approach has been utilized.

Furthermore, an

additional goal of these studies was to utilize network analysis to determine if the β androstene
hormones might have utility in their treatment of chronic pressure ulcers. Together, these studies
test the hypothesis that the β androstene hormones will achieve their cellular and molecular
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effects through actions that do not necessarily include the nuclear receptors.
Many studies have shown that application of β-androstene hormones resulted in an
interaction between different members of the nuclear receptors (androgen, estrogen receptor
alpha and estrogen receptor beta). Despite the ability of the androstene hormones to activate the
androgen and estrogen receptors, they have also been shown to elicit their biological effects in
cell lines devoid of the androgen and estrogen receptors. This is the first study which compares
the action of DHEA and its derivatives directly on the human androgen, estrogen, and
glucocorticoid receptors.
The inherent androgenicity and estrogenicity of these hormones has been controversial
and biological activity (cell proliferation) has been attributed to androgenicity and estrogenicity
of mainly DHEA and 17β-AED. These studies, for the first time, demonstrated the differences
between DHEA, 17α-AED, 17β-AED and 17β-AET and demonstrated a decrease of
androgenicity and estrogenicity that is on orders less than either testosterone or 17β-estradiol.
The initial studies sought to characterize the ability of DHEA, 17α-AED, 17β-AED and 17βAET to both bind the receptor and activate transcription in a cellular constructs containing
human nuclear receptors. Thus, these experiments would confirm prior reports and provide the
necessary information on 17α-AED and 17β-AET in relation to 17β-AED, which is known to be
a weak binder and activator, of the ESR1 and AR. Additionally, no information was currently
available for β androstene hormones binding and activation of the human ESR2.
The overall hypothesis of Chapter 1 was: Androstene Hormones will bind and activate
ESR1, ESR2, AR, and GR differently than their known ligands when compared concurrently on
whole cell constructs. Once obtained, the androstene hormone activity could then be compared
with the known ligands of the ERα, ERβ, AR or GR nuclear receptors. A second aim to this
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hypothesis was to determine if DHEA, 17α-AED, 17β-AED and 17β-AET influence binding and
activation of the glucocorticoid receptor when the receptor was activated with its known ligand
which would demonstrate if androstene hormones would produce anti-glucocorticoid activity at
the level of the human receptor.
The androstene hormones directly activated the ERα, ERβ and AR but at levels that were
orders of magnitude less than estradiol and testosterone. These studies demonstrated that the β
androstene hormones each produced unique, differential interactions and level of activation of
these human nuclear receptors indicating that there may be additional factors involved. This
result demonstrated that, at the receptor level, the binding and action of these hormones is
different than 17β-estradiol and testosterone on the human ERα, ERβ and AR and their activity
with these receptors may not be a requirement for their biological activity. Furthermore, these
observations support the hypothesis that the biological effects of the androstene hormones are
not primarily mediated through interaction with the human ERα, ERβ and AR. Consistent with
these observations, androstene hormones have been shown to promulgate their biological effects
when the estrogen and androgen receptors are not present. The results were consistent with prior
studies and extended the knowledge of the β androstene hormone interactions with the human
ERα, ERβ and AR.
Metabolites

of

DHEA

produced

intracellularly

[343],

such

as

17β-AED,

Androstenedione, testosterone and dihydrotestosterone will cause activation and transactivation
of ERα, ERβ and AR [344]. In Chapter 1 studies, DHEA did metabolize into 17β-AED and
therefore the activity of DHEA was, at least in part, due to 17β-AED in the nuclear receptor
assay cells, however, it was also demonstrated that, in these whole cell assay constructs, 17αAED, 17β-AED and 17β-AET were not transformed into any metabolites with the ability to bind

106

and transactivate the human nuclear receptors tested in Chapter 1. The results directly reflected
only the ability of 17α-AED, 17β-AED and 17β-AET to interact with these human nuclear
receptors.
Activity of 17β-AED has been associated with anti-glucocorticoid activity. It was not
known if these interactions occurred at the level of the receptor. Consequently, we pursued the
anti-glucocorticoid activity of the androstene hormones. 17α-AED, 17β-AED and 17β-AET did
not directly activate the GR and also did not inhibit the GR ligand, dexamethasone. Conversely,
there was differential activity of all the receptors, evidenced only at supra-high levels of
androstene hormone and dexamethasone, even in the presence of the AR and GR inhibitor:
cyproterone. These results extended the knowledge of the human GR receptor and demonstrated
in this construct that at very high concentrations of agonist there is an indirect interaction that
occurs outside the pocket of the human GR that affects the activation of the human GR. Thus,
anti-glucocorticoid activity that is produced by androstene hormones is derived externally to the
“active pocket” of the human GR.
No androstene hormone initiated activation of the human GR receptor and there was a
differential effect exhibited by DHEA, 17α-AED, 17β-AED and 17β-AET in the presence of
dexamethasone. Together, these observations with the differential biological anti-glucocorticoid
actions demonstrated by the androstene hormones indicate that the androstene hormones have a
differential, indirect effect on the human GR at the receptor level and may further indicate that
these hormones have the ability to modulate glucocorticoid activity. Further studies will need to
be performed to examine the biological actions produced by androstene hormones that result in
anti-glucocorticoid activity.
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The androstene hormones are known to produce diametrically opposite biological effects.
17α-AED is known to induce irreversible apoptosis in lymphoma cells (U937) and irreversible
autophagy in T98G, U87MG, LN-Z308 and GBM6 Glioblastoma Multiforme cell lines. The
chemically identical epimer of 17α-AED, 17β-AED, is known for protection against diverse
stressors and promotes cell survival. The main biological effect (irreversible autophagy) of 17αAED is now known to occur through the ER stress receptor, PERK, and is propagated through
eLF2α and CHOP (Gadd153) in Glioblastoma Multiforme cells. Studies ascribed a structural
relationship with its biological activity to 17α-AED. It was shown in these studies that the
hydroxyl group in the 3β position was dispensable in relation to biological activity but the
hydroxyl group at the 17α-postion was critical for the biological activity. Thus overall, we
demonstrate that the position of the hydroxyl group at the 17 position of 17β-AED, 17α-AED
and 17β-AET determines and the hydroxyl group at 7 position influences the biological activity
of these β-androstene hormones at the level of the ERα, ERβ, AR and GR receptors.
In chapter 1 we demonstrated that the structure related to the hydroxyl located at
positions 7 and 17 resulted in differential activation of a transcriptional reporter in whole cell
constructs. 17α-AED and 17β-AED are chemically identical and only differ at the position of the
hydroxyl at the 17 position with respect to the cycloperhydrophenanthrene ring of the hormone.
Since 17α-AED and 17β-AED are chemically identical and the biological effects of 17α-AED
and 17β-AED are opposing and the biological activity 17α-AED and 17β-AED is attributed to
the hydroxyl group at the 17 position and because the biological actions associated with the
irreversible cell death stimulated by 17α-AED is known, it was hypothesized that 17α-AED of
T98G Glioblastoma Multiforme cells would cause the cells to stimulate gene transcription
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resulting in irreversible cell death while 17β-AED treatment would stimulate gene transcription
that would result in cell survival.
Thus, one aim of this hypothesis was to identify a transcriptional, cell-directed genetic
program stimulated by 17α-AED that resulted in cell death while at the same time identifying the
transcriptional cell-directed genetic program stimulated by 17β-AED that results in cell survival.
Since androstene hormones are naturally produced in humans, this set of genes would also
represent a core geneset that human cells utilize to either promote survival or death. Thus broad
signal transduction microarray that contained 113 genes was performed on T98G Glioblastoma
Multiforme cells that were treated with either 17α-AED or 17β-AED. It was determined that
17α-AED or 17β-AED regulated 26 of 113 total genes by greater than one magnitude in opposite
directions (17β-AED >5 fold and 17α-AED <5 Fold). These twenty six genes are presented in
Chapter 2 and represent a specific, core set of genes involved in the transcriptional, cell-directed
genetic program stimulated by 17α-AED or 17β-AED that results in cell death or survival
respectively.
The identification of the core set of genes regulated in an opposing fashion by 17α-AED
and 17β-AED and aligned with the known biological results demonstrated that a transcriptional,
cell-directed program for cell death and survival exists for these epimers through this common
geneset. Thus, this led us to hypothesize that network analysis of this geneset could be utilized to
elucidate how these genes were associated with each other thus advancing our understanding of
the androstene hormone directed program of cellular life and death. The second aim of this study
was to further advance the understanding of the known biological action of 17α-AED and
delineate the action of 17β-AED. Together, these observations would advance our current
knowledge of how 17α-AED or 17β-AED influence cell directed life and death decisions.
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Network analysis was performed on the 26 member geneset. Network analysis was
extremely useful as the network scores could be utilized for 2 important functions. First,
networks (and thus gene groupings) could be ranked by most significant to least significant based
on the number and associations of the genes (genes included together within networks are termed
focus genes) within the network. Second, the gene groups represent associations of how these
genes may be organized biologically.
The overall results presented in Chapter 2 demonstrate that 17α-AED directs its actions
through PERK, an endoplasmic reticulum stress receptor, while downregulating BRCA1, BCL2,
GADD45, CDKN1A and IRF-1. In opposition, 17β-AED stimulated upregulation of BRCA1 and
BCL2 with a concomitant upregulation of GADD45, CDKN1A and IRF-1. When upregulated
together (Figure 13), this geneset implies that 17β-AED induces a program of DNA repair and
growth control. Microarray and Network analysis also implicated the action of WNT1 and its
subsequent action on GSK3β as key components to either stimulate or shut down the eukaryotic
translation initiation factor elF2α and upregulate or downregulate the core transcription regulator
p53. Furthermore, examination of the networks and the geneset provided evidence that AKT was
differentially modulated by these epimers. Examination of the core transcriptional regulators
demonstrated that p53 and RB/E2F core transcriptional units were implicated in the survival or
cell death associated with 17α-AED or 17β-AED.
Analysis of the genetic mutations that are common to Glioblastoma Multiforme and
application to T98G cells demonstrated that mutations exist in components of the
CDKN2A/MDM2/p53 axis, the PTEN and NF1 associated Ras/PI3K axis and the
CDKN2A/CDK4/RB axis. It could be seen that 17α-AED affected these pathways through
downregulation of the geneset while 17β-AED affected these pathways through upregulation of
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the geneset. Importantly, 17α-AED or 17β-AED exerted their biological effects in the T98G
Glioblastoma Multiforme cells despite the presence of mutations in the core transcriptional
regulators.
Demonstration of the existing common geneset along with the results presented in
Chapter 1 supports the idea that 17α-AED or 17β-AED exert their effects at least, in part,
through an opposing biological action which is related to the structural stereochemistry of these
two chemically identical hormones. The 26 gene set of common genes that are regulated in
opposition by 17α-AED or 17β-AED exist and many of them are either known transcriptional
master regulators or affect those regulators within the geneset. Through the use of 17α-AED or
17β-AED, T98G Glioblastoma Multiforme cells, microarray and network analysis it was
possible to demonstrate that an opposing biological action that includes transcriptional regulation
of a set of influential biological regulators exists and is related to the structural stereochemistry
of these two chemically identical hormones.
Core transcriptional regulators within the 17α-AED or 17β-AED common geneset can be
associated with cell directed programs of cell cycle control, cell death, angiogenesis inhibition
and metastasis or DNA Repair. It could be seen that 17α-AED achieved its effects through
downregulation of core transcriptional regulators and deactivation of translation initiation
resulting in cell death. Downregulation of the common geneset could be seen to augment the
action of 17α-AED and thus expands the current knowledge of how this androstene hormone
stimulates Glioblastoma Multiforme cells to direct cell death.
In opposition, upregulation of the common geneset delineated how 17β-AED propagated
its effects in Glioblastoma Multiforme cells. The upregulation of the common geneset suggests
that 17β-AED propagates a cellular program of DNA repair and growth control (Chapter 3).
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Finally, these observations along with the observations presented in Chapter 1 further support
and strengthen the argument that while androstene hormone activity is influenced by ERα, ERβ,
AR and GR these human nuclear receptors are not the primary arbiter of the cellular and
molecular activity of 17α-AED, 17β-AED and 17β-AED. Importantly, the 26 member geneset
identified how 17α-AED and 17β-AED stimulate cellular life and death decisions even in the
presence of genomic mutation and instability.
Chronic pressure ulcers in spinal cord injury patients represent a multi-factorial, hard-totreat condition that develops over time in patients with limited mobility. The environment of the
chronic wound is one of infection, hypoxia, repetitive ischemia/reperfusion, and an altered
cellular and stress response. Once a chronic pressure ulcer has formed it becomes a significant
health burden both to patients and the healthcare system. These wounds are particularly difficult
since spinal cord injury patients have limited mobility and the ulcers usually form from shear
pressures located on bony prominences.
Since, microarray and network analysis was useful in delineating the action of 17α-AED
or 17β-AED, this technique was again utilized to briefly analyze chronic pressure ulcer wound
edges and normal skin. 17α-AED and 17β-AED exert their effects through an ER stress sensing
action and their biological effects are promulgated through a common geneset containing master
transcriptional regulators. The master transcriptional regulators within the 17α-AED or 17β-AED
common geneset can be associated with cell directed programs of cell cycle control, cell death,
angiogenesis inhibition and metastasis or DNA Repair. These properties may indicate an
application for 17α-AED and/or 17β-AED in the treatment of chronic pressure ulcers.
Thus, we hypothesized that the master transcriptional regulators regulated by 17α-AED
or 17β-AED stimulated cells may underlie the altered cellular and systemic responses seen in the
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chronic wound environment. The primary aim was to identify the primary significant difference
between the chronic wound and the normal skin and then apply targeted network analysis of
these genes with the 17α-AED and 17β-AED common geneset that contains master
transcriptional regulators. Association of these regulators with the significant differences within
the wound indicates an application for androstene hormones.
The analysis revealed that networks were "rewired" in the chronic wound edges probably
reflecting the multi-factorial state known to be present in these wounds. For simplicity, a
complete review (Chapter 4) was performed only on network number 1 for two main reasons 1)
Network 1 is the most statistically significant network. 2) Network 1 contained mainly similar
genes between the chronic pressure and the normal skin. The primary observation is that
ubiquitin C is the central molecule of network 1 in both the chronic wound and the normal skin.
Review of the genes revealed that eight genes were different between the chronic
pressure ulcer and normal skin in network 1. Functional comparison demonstrated that the genes
associated with the chronic pressure ulcer do indeed reflect the multi-factorial state of the
chronic pressure ulcer while loss of the eight UBC-associated genes in the normal skin implies a
loss of skin functionality associated with theses genes. CERCAM and LMF2 were associated
with abnormal skin barrier function, abnormal collagen synthesis due to lack of glycosylation
and leukocyte transmigration. An important observation is that 17β-AED will significantly
increase CD11b/CD18 (MAC-1) after radiation [99]. Since CERCAM was shown to bind to
CD11b then the implication is that 17β-AED or 17β-AET would promote beneficial immune cell
trafficking and processes in the stress altered environment of the chronic pressure ulcer.
CLIP3 and SLC22A17 were related to cellular apoptosis while UBAP1 suggested
lysosomal degradation of EGFR which was accompanied by a transcriptional decrease in EGFR t
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while RNF24 and RNF145 represent E3 ligases involved in ubiquitination processes. Together,
these processes suggest that the ubiquitin-proteosomal system may be the central factor in
regulating the altered cellular and stress response of the chronic wound environment. The main
observation is the loss of association of UBC with genes that regulate barrier function in,
immunity and oxidative stress, in normal skin.
Targeted microarray analysis of the eight different genes demonstrated that p53, CDK2,
SQSTM1 and UBC were active in the regulation of CERCAM. UBAP1 demonstrated a more
complex interaction with the common geneset and the glucocorticoid receptor, EGR1, NAB2,
GADD45 and BRCA1 were implicated in the regulation of EGFR, which is significantly
downregulated and known to play a leading role in the cell survival and proliferation seen in
normal wound healing. In addition, CLIP3 analysis added cJUN to the list of regulators
associated with the eight UBC-associated genes that are present in the chronic pressure ulcer.
Additionally, EGFR was associated with the presence of the glucocorticoid receptor
(Figure 19). The glucocorticoid receptor is known to counteract the activity of the EGFR [346].
Furthermore, the glucocorticoid receptor is known to predispose individuals with chronic stress
to mental anxiety, immune deficiency, inflammatory dysregulation and impair wound healing
[347][348][349][112]. It has been shown prior that androstene hormones can counteract the
glucocorticoid receptor [73] and stress-impaired wound healing [112][170]. It is demonstrated
here that the androstene hormones interact indirectly and have applicability to the treatment of
chronic wounds since it is demonstrated here that the androstene hormones influence the human
GR indirectly, influence biological activity of the human GR and a subset of the 26 genes known
to be transcriptionally regulated by androstene hormones (core regulators) are associated with the
UBC-associated genes unique to the chronic pressure ulcers.
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A critical observation is that NCCRP-1, CERCAM, ThumpD1, DEF8, CLIP3, RNF24,
SLC22A17, UBAP1 were genes in both the normal and chronic pressure ulcer skin that represent
activity of the innate immune system. Thus, NCCRP-1, ThumpD1, and DEF8 loss of association
with UBC in the chronic pressure ulcer represents a loss of normal innate immune function while
the association of CERCAM, CLIP3, RNF24, SLC22A17 and UBAP1 represent an abnormal
innate immune function in non-healing skin. Since abnormal innate immune functions are
associated with non-healing pressure ulcers then these genes can be seen as primary targets of
therapies targeting chronic pressure ulcers.
Three main observations demonstrate that 17β-AED and 17β-AET may be effective
therapeutics in the chronic wound environment. First, these hormones are known to increase
effective innate immune processes in the presence of stress demonstrated by modulation of
innate immune cytokines and effective cellular responses. Second, these hormones are known to
counteract the effects of the glucocorticoid receptor also through the modulation of innate
immune cytokines and cellular responses. Third, 17β-AED is now known to initiate a cellular
program of DNA repair, growth control and immunity through the modulation of transcriptional
regulators.
The androstene hormones are known to be beneficial to stress-related delayed wound
healing and provide the means to discover how core transcriptional regulators can themselves be
regulated to influence the eight genes uniquely associated with the ubiquitin-proteosomal system
in the chronic wounds. Thus, counteracting the action of the GCR receptor and initiating an
effective innate immune response may lead to new and effective therapies in the treatment of
chronic pressure ulcers. The genes identified in this analysis may represent treatment biomarkers
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which can guide treatments aimed at improve healing or the effectiveness of existing therapies
such as application of skin substitutes.
Future studies will need to be performed to elucidating the structure-function relationship
of the androstene hormones to further expand on what is now known. Elucidation of interactions
between the core regulators and UBC will be critical in understanding how the androstene
hormones influence broad biological regulatory processes, including protein production
(transcription and translation), modification (phosphorylation, acetylation, ubiquitination etc.)
and degradation (proteosomal, lysosomal and autophagic). Understanding how the
transcriptional, cell-directed programs stimulated by androstene hormones influence broad
biological regulatory processes such as innate immunity or counteract the action of
glucocorticoids will illuminate how these adrenal cortical steroids achieve their remarkable
biological effects and may result in treatments with applicability to many complex, hard-to-treat
or currently untreatable human conditions.
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APPENDIX 4-A

Normal Skin, Network 1, UBC-associated Gene Information
Symbol

Synonym(s)

Entrez Gene
Name

Illumina ID/
Accession

KPRP

1110001M24Rik,

Keratinocyte

ILMN_1780649/

AA589586,
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NM_001025231.1

C1orf45

protein

1190020J12Rik,

non-specific

ILMN_1713397/

FBXO50,

cytotoxic cell

NM_001001414.1

Gm163,

receptor protein

RGD1305932

1 homolog

NCCRP1

Human
Entrez
Gene ID
448834

342897

(zebrafish)
THUMPD1

6330575P11Rik

THUMP

ILMN_2108339/

domain

NM_017736.3

55623

containing 1
DEF8

AI449518,

differentially

ILMN_1767509/

D8Ertd713e,

expressed in

NM_207514.1

FLJ20186

FDCP 8

54849

homolog
(mouse)
MMGT1

9630048L06Rik,

membrane

ILMN_1776216/

BC032271,

magnesium

NM_173470.1

EMC5,

transporter 1

RGD1566339,
RP11-274K13.3,
TMEM32
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93380

Normal Skin, Network 1, UBC-associated Gene Information (Continued)
Symbol

Synonym(s)

Entrez Gene
Name

Illumina ID/
Accession

SECISBP2L

3110001I20Rik,

SECIS

ILMN_1784333/

AI504340,

binding

NM_024077.2

C630011I23,

protein 2-like

Human
Entrez
Gene ID
9728

RGD1559930,
RP23-367K9.1,
SLAN
BEX4

BEXL1,

Brain

ILMN_1804798/
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Expressed

NM_001006937.1

RP23-1A3.7,

X-Linked 4

56271

RP4-635G19.2
RILPL1
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Rab

ILMN_1805643/

6330559I19Rik,

interacting

NM_178314.2

GOSPEL,

lysosomal

MNCb-2440,

interacting
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protein-like 1

RLP1
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APPENDIX 4B
Chronic Pressure Ulcer Skin Edge, Network 1, UBC-associated Gene Information
Symbol

Synonym

Entrez Gene
Name

Illumina ID/
Accession

Human
Entrez
Gene ID

CERCAM

2600006K01RIK,

cerebral

ILMN_1750563/
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endothelial

NM_016174.3

CEECAM1,

cell
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adhesion

RP11-339B21.2,

molecule
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LMF2
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lipase

ILMN_1716056/

RGD1306274,

maturation

NM_033200.1

TMEM153,

factor 2
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CLIP3

SLC22A17
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CAP-GLY

ILMN_1789733/
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domain

NM_015526.1

CLIPR-59,

containing

RGD1306245,

linker

RSNL1

protein 3

24p3R,

solute

ILMN_1653200/

1700094C23Rik,

carrier

NM_016609.3

AU041908,

family 22,

AW555662,

member 17

BOCT, BOIT,
hBOIT, Lcn2 receptor,
mBOCT, NGALR2,
NGALR3, NGALR,
RBOCT
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Chronic Pressure Ulcer Skin Edge, Network 1, UBC-associated Gene Information
(Continued)
Symbol

Synonym

Entrez Gene
Name

Illumina ID/
Accession

Human
Entrez
Gene ID

UBAP1

2700092A01Rik,

ubiquitin

ILMN_1807596/

51271

NAG20,

associated

NM_016525.3

RP11-571F15.1,

protein 1

RP23-328E6.5,
UAP, UBAP
RNF24

2810473M14RIK,

ring finger

ILMN_1717809/

4930505A13Rik,

protein 24

NM_007219.2

3732413I11RIK,

ring finger

ILMN_1710906/

FLJ31951,

protein 145

NM_144726.1

9130401M01Rik,

chromosome

ILMN_1742074/

AI849328,

8 open

NM_032847.1

RGD1310852

reading

11237

AI317164,
C86507,
D2Ertd504e,
G1L,
RP23-387C21.6
RNF145

153830

RGD1309561,
RP23-103H9.1,
TMRF1
C8orf76

frame 76
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APPENDIX 4C
Table of UBC-associated Genes Shared in Network 1 of Chronic Pressure Ulcer and Normal
Skin Edges
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